var title_f37_11_38064="Erythromycin: Pediatric drug information";
var content_f37_11_38064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Erythromycin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12624527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/41/42642?source=see_link\">",
"       Erythromycin (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/32/22025?source=see_link\">",
"       Erythromycin (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/6/30818?source=see_link\">",
"       Erythromycin (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13276 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-287B6DBA01-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_11_38064=[""].join("\n");
var outline_f37_11_38064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/41/42642?source=related_link\">",
"      Erythromycin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/32/22025?source=related_link\">",
"      Erythromycin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/6/30818?source=related_link\">",
"      Erythromycin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_11_38065="EP study APB";
var content_f37_11_38065=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electrophysiology (EP) study showing surface and intracardiac electrocardiogram tracings of an atrial premature beat (APB)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Simultaneous surface electrocardiographic leads I, II, V1 and intracardiac recordings from the high right atrium (HRA), His bundle (HBE), proximal (CSp) and distal (CSd) coronary sinus, and right ventricular apex (RVA). During sinus rhythm the impulse originates in the HRA and is then conducted through the HBE, CSp, CSd, and ultimately the RVA (blue line 1). An atrial premature beat (ABP), denoted by the red asterisk, originates in the CSp (blue line 2) and is conducted retrogradely to the HRA and antegradely to the CSd and RVA. The APB has a longer AH interval compared to sinus rhythm and is associated with a full compensatory pause.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_11_38065=[""].join("\n");
var outline_f37_11_38065=null;
var title_f37_11_38066="Patient information: Managing diabetes in school (The Basics)";
var content_f37_11_38066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/52/37699\">",
"         Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/26/39331\">",
"         Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?5/33/5651\">",
"         Patient information: Giving your child insulin (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/25/36243\">",
"         Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/48/18179\">",
"         Patient information: My child has diabetes: How will we manage? (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/43/692\">",
"         Patient information: Type 1 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/31/35317\">",
"         Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/43/39603\">",
"         Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/20/3397\">",
"         Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Managing diabetes in school (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/managing-diabetes-in-school-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2056078\">",
"      <span class=\"h1\">",
"       Should I tell the school that my child has diabetes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, let your child&rsquo;s school know right away if he or she has diabetes (or &ldquo;diabetes mellitus&rdquo;).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2056093\">",
"      <span class=\"h1\">",
"       Who will manage my child&rsquo;s diabetes in school?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most likely, 1 main person will help to manage your child&rsquo;s diabetes in school. If your school has a nurse, he or she will be the main person. If not, another staff member can be the main person. If this person does not know how to take care of diabetes, he or she will need to learn how.",
"     </p>",
"     <p>",
"      Your child can also help manage his or her diabetes in school. As your child gets older, he or she can do more and more to manage it. But even if your child manages the diabetes on his or her own, a staff member at school should know about it and be ready to help in case of a diabetes emergency.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2056108\">",
"      <span class=\"h1\">",
"       What should the school do to manage my child&rsquo;s diabetes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The school should work with you and your child&rsquo;s diabetes team to make a written plan. This plan will list all the ways that the school will manage your child&rsquo;s diabetes. The school should let you know if they have questions about your child&rsquo;s diabetes or if any new problems come up.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2056123\">",
"      <span class=\"h1\">",
"       What information should be in my child&rsquo;s school plan?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your child&rsquo;s school plan should have information about how to take care of the diabetes day to day. It should also have information about how to treat problems or emergencies that might happen. The plan should include information from both you and your child&rsquo;s doctor about:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Your child&rsquo;s medicines &ndash; This should include all the medicines your child takes, where they are kept, and when and how they are given. The timing and dosing of your child&rsquo;s insulin are especially important.",
"       </li>",
"       <li>",
"        Your child&rsquo;s meals and snacks &ndash; For example, the plan might list foods that your child should or shouldn&rsquo;t eat. If your child needs to eat on a schedule, it can list the times and amounts that he or she should eat.",
"       </li>",
"       <li>",
"        Checking your child&rsquo;s blood sugar level &ndash; The plan should discuss who will check your child&rsquo;s blood sugar, and when and how it will be checked.",
"       </li>",
"       <li>",
"        Symptoms that could mean your child&rsquo;s blood sugar level is too low or too high &ndash; Let the school know which symptoms to watch for.",
"       </li>",
"       <li>",
"        How to treat a blood sugar level that is too low or too high, including when to get emergency help",
"       </li>",
"       <li>",
"        How to reach you, another family member, and your child&rsquo;s doctor in case of an emergency",
"       </li>",
"       <li>",
"        How to safely include your child in physical activities, school parties, field trips, and other special events",
"       </li>",
"       <li>",
"        Your child&rsquo;s other needs &ndash; For example, your child might need to leave class at certain times of the day to take insulin, use the bathroom, or eat a snack.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The person who manages your child&rsquo;s diabetes in school should share this plan with the other school staff. He or she should tell them how your child&rsquo;s diabetes will be managed, which symptoms to watch for, and what to do in case of an emergency.",
"     </p>",
"     <p>",
"      Every year before the school year starts, you and the school should review your child&rsquo;s plan. You might need to change the plan as your child gets older.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2056138\">",
"      <span class=\"h1\">",
"       What can I do to help the school manage my child&rsquo;s diabetes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help the school manage your child&rsquo;s diabetes, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Bring in the diabetes supplies that your child will need at school &ndash; This can include daily medicines, blood testing supplies, and emergency medicines.",
"       </li>",
"       <li>",
"        Leave food or snacks for your child at school &ndash; You might want to make up snack bags that the school can give your child if his or her blood sugar gets too low.",
"       </li>",
"       <li>",
"        Offer to teach the staff and students about diabetes and how it is managed",
"       </li>",
"       <li>",
"        Share information about your child&rsquo;s health with the school and let them know if anything changes with your child&rsquo;s diabetes",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2056153\">",
"      <span class=\"h1\">",
"       What else should I know?",
"      </span>",
"      &nbsp;&mdash;&nbsp;By law (in the United States), most schools must meet the needs of children with diabetes. If your school has a problem meeting your child&rsquo;s needs, talk with your child&rsquo;s doctor or nurse. You can also look at diabetes websites, such as the American Diabetes Association (",
"      <a class=\"external\" href=\"file://www.diabetes.org/\">",
"       www.diabetes.org",
"      </a>",
"      ) and the Juvenile Diabetes Research Foundation (",
"      <a class=\"external\" href=\"file://www.jdrf.org/\">",
"       www.jdrf.org",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2056168\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=see_link\">",
"       Patient information: Type 1 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/48/18179?source=see_link\">",
"       Patient information: My child has diabetes: How will we manage? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/33/5651?source=see_link\">",
"       Patient information: Giving your child insulin (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/26/39331?source=see_link\">",
"       Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/25/36243?source=see_link\">",
"       Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/52/37699?source=see_link\">",
"       Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/31/35317?source=see_link\">",
"       Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=see_link\">",
"       Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/20/3397?source=see_link\">",
"       Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/11/38066?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16599 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-C38B34FA94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_11_38066=[""].join("\n");
var outline_f37_11_38066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2056078\">",
"      Should I tell the school that my child has diabetes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2056093\">",
"      Who will manage my child&rsquo;s diabetes in school?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2056108\">",
"      What should the school do to manage my child&rsquo;s diabetes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2056123\">",
"      What information should be in my child&rsquo;s school plan?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2056138\">",
"      What can I do to help the school manage my child&rsquo;s diabetes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2056153\">",
"      What else should I know?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2056168\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/52/37699?source=related_link\">",
"      Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/26/39331?source=related_link\">",
"      Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/31/35317?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/33/5651?source=related_link\">",
"      Patient information: Giving your child insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/25/36243?source=related_link\">",
"      Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/48/18179?source=related_link\">",
"      Patient information: My child has diabetes: How will we manage? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/20/3397?source=related_link\">",
"      Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_11_38067="Normal human myeloblast";
var content_f37_11_38067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal human myeloblasts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear showing two normal human myeloblasts. The size is medium (15 to 20 microns in diameter), the nucleus is large and round with finely granular chromatin, nucleoli are present, granules are absent, and cytoplasm is scanty.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Baehner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_11_38067=[""].join("\n");
var outline_f37_11_38067=null;
var title_f37_11_38068="Triazolam: Patient drug information";
var content_f37_11_38068=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Triazolam: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/49/23319?source=see_link\">",
"     see \"Triazolam: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/37/7766?source=see_link\">",
"     see \"Triazolam: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Halcion&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F230773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Triazo&reg;;",
"     </li>",
"     <li>",
"      Gen-Triazolam;",
"     </li>",
"     <li>",
"      Halcion&reg;;",
"     </li>",
"     <li>",
"      Mylan-Triazolam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703076",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to triazolam or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for more than 10 days, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Driving or doing other tasks or actions that you do not remember doing after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696091",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug only for short periods of time (7 to 10 days).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet can be crushed and mixed with food or liquid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11121 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_11_38068=[""].join("\n");
var outline_f37_11_38068=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230772\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230773\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022133\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022135\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022134\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022139\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022140\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022142\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022137\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022138\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022143\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022144\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/49/23319?source=related_link\">",
"      Triazolam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/37/7766?source=related_link\">",
"      Triazolam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_11_38069="Fludrocortisone: Patient drug information";
var content_f37_11_38069=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fludrocortisone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=see_link\">",
"     see \"Fludrocortisone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/32/44549?source=see_link\">",
"     see \"Fludrocortisone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Florinef&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Addison's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692048",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat salt-losing diseases.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691934",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702133",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fludrocortisone acetate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700365",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bad yeast infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid being near anyone with chickenpox or measles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697224",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma or cataracts, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are being treated for any infection, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have stomach ulcers, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697345",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have TB (tuberculosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697932",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cataracts or glaucoma with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin changes (pimples, stretch marks, slow healing, hair growth).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698252",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness, mostly in the thighs and upper arms.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698688",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been exposed to chickenpox and have not had chickenpox or had a chickenpox vaccine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695878",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take in the morning if taking once a day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12477 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-0ACB48A304-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_11_38069=[""].join("\n");
var outline_f37_11_38069=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171956\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020857\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020859\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020858\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020863\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020864\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020866\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020861\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020862\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020867\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020868\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=related_link\">",
"      Fludrocortisone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/32/44549?source=related_link\">",
"      Fludrocortisone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_11_38070="Everolimus: Patient drug information";
var content_f37_11_38070=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Everolimus: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     see \"Everolimus: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/41/20121?source=see_link\">",
"     see \"Everolimus: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7418605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Afinitor&reg;;",
"     </li>",
"     <li>",
"      Afinitor&reg; Disperz;",
"     </li>",
"     <li>",
"      Zortress&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13209898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Afinitor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-term use may raise the chance of cancer and unsafe infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2762142",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Zortress&reg;",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2762140",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A blood clot may happen in your kidney transplant. Call your doctor right away if you have back or belly pain, are not able to pass urine, have blood in your urine, a fever, an upset stomach, or you are throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2762141",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug with cyclosporine, you will need a lower dose of cyclosporine. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3761649",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat certain kinds of kidney cysts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to keep the body from harming the organ after an organ transplant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705245",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to everolimus, temsirolimus, sirolimus, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697657",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a chance of skin cancer. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697654",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The chance of cancer is higher after using this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697269",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high cholesterol, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3761650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a heart transplant, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are being treated for any infection, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697828",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust during care and for 2 months after care ends.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698150",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High triglyceride level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698227",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the lungs may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney failure may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin wound that will not heal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3761703",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. If you take with food, always take with the same amount and kinds of food each time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2762144",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take Zortress&reg; at the same time as you take cyclosporine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3890502",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Disperz tablets:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3890523",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as a liquid only. Do not swallow tablets whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2956563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with water as you have been told before drinking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3890522",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink right after mixing. Throw away any part not used after 1 hour.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696588",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it has been 6 hours or more since the missed dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699399",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in the original container at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12172 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_11_38070=[""].join("\n");
var outline_f37_11_38070=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7418605\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13209898\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020403\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020405\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020404\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020409\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020410\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020412\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020407\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020408\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020413\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020414\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=related_link\">",
"      Everolimus: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/41/20121?source=related_link\">",
"      Everolimus: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_11_38071="Evaluation and management of suicidal behavior in children and adolescents";
var content_f37_11_38071=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and management of suicidal behavior in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/11/38071/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/11/38071/contributors\">",
"     Stephanie Kennebeck, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/11/38071/contributors\">",
"     Liza Bonin, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/11/38071/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/11/38071/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/11/38071/contributors\">",
"     Daniel M Lindberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/11/38071/contributors\">",
"     David Brent, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/11/38071/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/11/38071/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/11/38071/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suicidal behavior includes the spectrum from thoughts or ideas that revolve around suicide or death (suicidal ideation) through fatal completion of suicide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Between these extremes are suicide threats and suicide attempts (potentially self-injurious action with a nonfatal outcome for which there is evidence that the individual intended to kill him or herself) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/1\">",
"     1",
"    </a>",
"    ]. Children and adolescents who present for medical attention with suicidal behavior require a variable amount of medical, social, and psychiatric intervention depending upon the seriousness of their intent, their underlying risk factors, and their emotional support system.",
"   </p>",
"   <p>",
"    The evaluation and management of children and adolescents with suicidal ideation will be reviewed here. The epidemiology of and risk factors for childhood and adolescent suicide are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23834?source=see_link\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IDENTIFICATION OF SUICIDE RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of suicide involves identification of at-risk youth before suicidal behavior emerges. Clinicians play a central role in prevention since they are well positioned to identify and pursue early treatment for children and adolescents at-risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23834?source=see_link\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Association of Suicidology developed a mnemonic (\"is path warm?\") to help identify key warning signs for suicide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ideation &mdash; Talking about or threatening to kill or hurt oneself; looking for ways to kill oneself; talking or writing about death, dying or suicide",
"     </li>",
"     <li>",
"      Substance abuse &mdash; Increased substance use",
"     </li>",
"     <li>",
"      Purposelessness",
"     </li>",
"     <li>",
"      Anxiety &mdash; Anxiety, agitation, or changes in sleep pattern",
"     </li>",
"     <li>",
"      Trapped &mdash; Feeling like there is no way out",
"     </li>",
"     <li>",
"      Hopelessness",
"     </li>",
"     <li>",
"      Withdrawal &mdash; Withdrawing from friends, family, and society",
"     </li>",
"     <li>",
"      Anger",
"     </li>",
"     <li>",
"      Recklessness",
"     </li>",
"     <li>",
"      Mood changes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Asking about suicide",
"    </span>",
"    &nbsp;&mdash;&nbsp;A most basic means to identify at-risk youth involves simply asking about suicidal thoughts, intent, and risk factors as part of routine health care. The concern that talking or asking about suicide will initiate suicidal actions or ideation in a child or adolescent is not supported by evidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/19000?source=see_link&amp;anchor=H4#H4\">",
"     \"Guidelines for adolescent preventive services\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following areas should be included in adolescent health screening:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous suicide attempts",
"     </li>",
"     <li>",
"      Recent serious suicidal preoccupation",
"     </li>",
"     <li>",
"      Depression",
"     </li>",
"     <li>",
"      Alcohol or substance abuse",
"     </li>",
"     <li>",
"      History of interpersonal violence or witnessing domestic violence as a child",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician's demonstration that he or she is comfortable discussing suicide is an important element of an effective inquiry. Toward this end, the questions that are posed should be short, to the point, and asked in a non-judgmental manner in developmentally appropriate language [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/6\">",
"     6",
"    </a>",
"    ]. Sample questions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Do you ever think about dying? How often?",
"     </li>",
"     <li>",
"      What do you think happens when you die?",
"     </li>",
"     <li>",
"      Have you ever wished you were dead?",
"     </li>",
"     <li>",
"      Do you ever think the world would be better off if you were dead? Do you think life would be easier for your family and friends if you were dead? Have you ever thought of what would have to happen for your life to end?",
"     </li>",
"     <li>",
"      Have you had thoughts about hurting yourself? Killing yourself?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the child or adolescent begins talking about suicidal thoughts, the lines of communication must be kept open. This can be facilitated through active listening, patience, maintenance of a calm demeanor, and neither minimizing the patient's concerns, nor reacting with disapproval. The natural tendency to be reassuring and optimistic must be inhibited. Attempts to talk the child or adolescent out of suicide should be avoided, as should discussions of whether suicide is right or wrong. In addition, confidentiality should not be promised since it cannot be maintained under these circumstances. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/2/10281?source=see_link&amp;anchor=H9#H9\">",
"     \"Confidentiality in adolescent health care\", section on 'Suicidal ideation or attempt'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a child or adolescent has disclosed suicidal ideation, prompt assessment of suicidal risk is in order. Risk for suicide should be considered imminent in patients who report an active plan or intent and have access to lethal means. The clearer the intent, the higher the risk, particularly in the context of disinhibition (eg, impulsivity or intoxication) and access to lethal means.",
"   </p>",
"   <p>",
"    A brief focused screening tool may have some value in identifying risk for suicidality when administered by nonmental health clinicians. The combination of inquiring about current suicidal behavior, past suicidal ideation, past self-destructive behavior, and current stressors yielded the highest sensitivity and identified 98 percent of children at risk for suicide in comparison to the assessment performed by trained mental health clinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A thorough risk assessment includes evaluation of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The content, nature, and chronicity of the suicidal thoughts (",
"      <a class=\"graphic graphic_table graphicRef54465 \" href=\"mobipreview.htm?24/13/24796\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The existence and details of a suicide plan (",
"      <a class=\"graphic graphic_table graphicRef54465 \" href=\"mobipreview.htm?24/13/24796\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Access to the means described in the plan (",
"      <a class=\"graphic graphic_table graphicRef54465 \" href=\"mobipreview.htm?24/13/24796\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other factors related to motivation,",
"      <span class=\"nowrap\">",
"       emotional/behavioral",
"      </span>",
"      regulation, support systems and stressors (",
"      <a class=\"graphic graphic_table graphicRef67228 \" href=\"mobipreview.htm?17/50/18220\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk assessment information should be obtained from several sources, including the child or adolescent, parents or guardians, school reports, therapists and behavioral staff, and other individuals who are close to the child or adolescent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/2\">",
"     2",
"    </a>",
"    ]. This is because the child or adolescent may have reason to provide inaccurate information (eg, to avoid hospitalization). Because children may not be able to accurately assess lethality, suicide risk assessment in children should be based upon the child's perception of lethality rather than the objective lethality of the suicidal act [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intervention/referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a child or adolescent is in an acute suicidal crisis, the focus of the intervention is to keep him or her safe until the suicidal state diminishes or abates. This usually involves working with the family or other supportive individuals who can address safety concerns (eg, remove access to means) and are willing to stay with the child or adolescent at all times.",
"   </p>",
"   <p>",
"    Treatment options may include hospitalization, medication, more frequent psychological intervention, mobilizing supports, access to crisis intervention services, and no-suicide contracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/9\">",
"     9",
"    </a>",
"    ]. The level of intervention depends upon the level of suicide risk, available support, and the ability of the child or adolescent to join with those who seek to keep him or her safe. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk assessment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate psychiatric evaluation (through the emergency department or psychiatry crisis clinic)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hospitalization is indicated when there is an imminent risk of suicide (eg, an active plan or intent without solid support or psychiatric or psychological intervention already in place to maintain safety) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/6,10-13\">",
"       6,10-13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Referral to a mental health professional is warranted if the risk is not imminent. However, consideration of the availability of the mental health professional is important, so as to avoid delays in needed treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The confidentiality of the adolescent who is at risk to harm him- or herself must be breached in deference to his or her safety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/10\">",
"     10",
"    </a>",
"    ]. An adolescent who agrees to a \"no-suicide\" contract is still at very high risk; this agreement does not protect the patient or the clinician. The agreement to a \"no-suicide\" contract should not be substituted for thorough evaluation, therapeutic interaction, or sound clinical judgment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], particularly in an impulsive adolescent. The efficacy of such contracts has not been proven, although they may help in fostering a therapeutic alliance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/14,16,17\">",
"     14,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EMERGENCY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents with suicidal behavior are typically evaluated in an emergency department. Medical stabilization is the first priority for those who have attempted suicide. The manner in which children and adolescents with suicidal behavior and their families are treated by the emergency department staff may affect compliance with follow-up care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/18\">",
"     18",
"    </a>",
"    ]. The importance of treatment should be stressed by both the emergency department and crisis team staff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Children and adolescents with suicidal behavior should have one-to-one attention until the seriousness of their intent is evaluated by the appropriate mental health or emergency department personnel. Potentially harmful medical supplies and equipment should be removed from the examination room where the patient is to be evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/6\">",
"     6",
"    </a>",
"    ]. To discourage elopement, a hospital gown should be provided to the patient and his or her clothing should be stored separately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The unique challenge of caring for children and adolescents with suicidal behavior requires careful deliberation and planning for emergency department staff. Emergency departments may need to review their care system and modify their physical structure to provide a safe and contained environment for these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/20\">",
"     20",
"    </a>",
"    ]. Potential areas of modification include: more mental health training, better access to mental health records, the development of crisis plans for adolescents at risk, and provision of additional staff (eg, security and other personnel who play a role in observation of the at-risk patient).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     History and examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The important aspects of the history that should be included in evaluation of the child or adolescent with suicidal behavior are discussed in the psychiatric evaluation. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Psychiatric evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The physical examination should be performed with attention to vital signs, level of consciousness and orientation, and manifestations of toxidromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, signs of previous suicide attempts (scars from cutting, bruises from hanging), physical or sexual abuse (characteristic bruising patterns, genital trauma), substance abuse (track marks from intravenous drug use, nosebleeds or perioral blisters from inhalant use), and organic disease (eg, thyroid disease) should be sought [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=see_link\">",
"     \"Evaluation of sexual abuse in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation of the child or adolescent with suicidal behavior should be individualized according to the circumstances of the ideation or attempt and the clinical risk assessment for concerns of illicit drug use and confounding medical problems, such as pregnancy and presence of sexually transmitted infections. Studies to be considered include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Toxicology screening, particularly for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      , tricyclic antidepressants, and illicit drugs",
"     </li>",
"     <li>",
"      Pregnancy test in girls",
"     </li>",
"     <li>",
"      Quantitative drug or alcohol screening",
"     </li>",
"     <li>",
"      Tests for organic causes of psychiatric conditions (eg, thyroid disease, inflammatory bowel disease, systemic lupus erythematosus, Wilson disease) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/21,22\">",
"       21,22",
"      </a>",
"      ] (see appropriate topic reviews)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Psychiatric evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychiatric evaluation should proceed after the patient is medically stable. The goals of the psychiatric evaluation include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Determination of the risk of suicide completion or subsequent attempt",
"     </li>",
"     <li>",
"      Identification of predisposing and precipitating factors that can be treated or modified",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The psychiatric evaluation should be performed by a clinician who has specialized training and experience in the psychiatric problems of children and adolescents. In some situations (ie, if a person with such training is not available), it may be necessary for an emergency department clinician to perform the initial evaluation to determine whether the patient should be transferred to another facility for a formal psychiatric evaluation. The information used in the evaluation should be gathered from several sources, including the child or adolescent, parents or guardians, school reports, previous psychiatric evaluation or assessments, and any other individuals who are close to the child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/2\">",
"     2",
"    </a>",
"    ]. This is because the child or adolescent may have reason to providing inaccurate information (eg, to avoid hospitalization).",
"   </p>",
"   <p>",
"    Three main areas should be addressed when evaluating the seriousness of suicidality and the risk for future attempts or completion. These areas are discussed in detail above and include suicidal ideation, plan, and intent (the balance between the wish to live and the wish to die). Information regarding underlying psychiatric or medical diagnoses and the inciting event also are important when assessing suicide risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/2\">",
"     2",
"    </a>",
"    ]. The use of the \"MALPRACTICE\" mnemonic can help to ensure that all of these areas are addressed (",
"    <a class=\"graphic graphic_table graphicRef63368 \" href=\"mobipreview.htm?43/33/44572\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk assessment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical stabilization of the patient who has attempted suicide is the first priority. The appropriate surgical service should be contacted for management of trauma. Patients whose attempt involved drug ingestion should undergo decontamination and receive antidotes as indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/12/7367?source=see_link\">",
"     \"Classification of trauma in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=see_link\">",
"     \"Decontamination of poisoned children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13114?source=see_link\">",
"     \"Management of acetaminophen (paracetamol) poisoning in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19098?source=see_link\">",
"     \"Salicylate poisoning in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disposition of the suicidal child or adolescent from the emergency department or medical care depends upon the immediate risk of suicide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/6\">",
"     6",
"    </a>",
"    ]. Children and adolescents should not be discharged from medical care until their account of events has been verified by their caregiver(s) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychiatric hospitalization for formal evaluation and initiation of therapy is usually indicated for children and adolescents with immediate high risk of suicide. Individuals at immediate high risk of suicide include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Those who have used high lethality methods or taken steps to avoid detection",
"     </li>",
"     <li>",
"      Those with psychiatric disorders",
"     </li>",
"     <li>",
"      Those with current intoxication or history of substance abuse",
"     </li>",
"     <li>",
"      Those with inability to develop trusting relationships with medical clinicians",
"     </li>",
"     <li>",
"      Those with poor social support",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hospitalization for such individuals is the traditional standard of care, although it has not been proven to be effective in preventing subsequent suicide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While awaiting such placement, the patient should be kept in a private room, with all sources of potential harm removed. Family may be present if the patient desires. A staff member should be assigned to stay with the patient at all times. Transfer of the patient should take place by ambulance, and the paramedics must be aware of the suicide risk. Restraints should only be used if the patient is actively seeking ways to harm self or others, although the proper use of restraints should be part of the educational curriculum for Emergency Department clinical staff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/23\">",
"     23",
"    </a>",
"    ]. The use of pharmacologic agents to sedate an aggressive or out of control adolescent should be undertaken with caution because of the potential side effects of these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/24\">",
"     24",
"    </a>",
"    ]. Inpatient treatment should continue until the mental state or level of suicidality has stabilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Involuntary hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;It may be necessary to consider involuntary hospitalization if the parents or legal guardian of the child are not present",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    are not in agreement with the clinician's plans for hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/12\">",
"     12",
"    </a>",
"    ]. The mechanisms for hospitalization of a person who will not or cannot sign themselves into a hospital vary from state to state. Most states require that the patient be a danger to self or others",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    substantially unable to care for him or herself.",
"   </p>",
"   <p>",
"    Patients who are admitted against their will, or the will of their guardians, maintain the autonomy to consent for treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/12\">",
"     12",
"    </a>",
"    ]. The only medications that can be administered without their consent, or the consent of their guardians, are those that are necessary for stabilization during a crisis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Intensive home therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensive home therapy may be an option for some patients who need crisis stabilization. In one study, 113 youth in need of psychiatric crisis stabilization were randomly assigned to psychiatric hospitalization or multisystemic therapy (MST) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients were followed for approximately four months, the time required to complete MST therapy; measured outcomes included subsequent hospitalization and out-of-home placement. MST prevented hospitalization for 57 percent of the participants, reduced overall number of days hospitalized by 72 percent, and reduced days in other out-of-home placement by 49 percent. Although these results are encouraging, decisions regarding disposition and ongoing therapy should be made by a clinician with training and expertise in child and adolescent psychiatry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Outpatient therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outpatient therapy is usually the best option for lower risk individuals (eg, patients who are medically stable and are not imminently suicidal) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/19,25\">",
"     19,25",
"    </a>",
"    ]. Outpatient therapy requires the involvement of the family and their willingness to stay with the patient indefinitely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/2,12,13\">",
"     2,12,13",
"    </a>",
"    ]. All lethal means of suicide, particularly firearms and medications, should be made unavailable to the patient. The acute crises that precipitated the event must be addressed and attempts made to resolve them. The patient and parents should be warned about the dangerous disinhibiting effects of alcohol and other drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/2\">",
"     2",
"    </a>",
"    ]. Psychiatric follow-up must be secured within 48 hours and the patient and family members should be instructed to return to the emergency department if things are not going well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergent administration of antidepressants has no role in the acute management of the suicidal adolescent or child. The efficacy of tricyclic antidepressants (TCAs) in childhood and adolescent depression has not been demonstrated; nor is there evidence that the use of TCAs decreases suicide risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, the small difference between therapeutic and toxic concentrations for these drugs makes them potentially lethal.",
"   </p>",
"   <p>",
"    Selective serotonin reuptake inhibitors (SSRIs) are usually better tolerated by children and appear to be more promising than TCAs for treating depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/2\">",
"     2",
"    </a>",
"    ]. They have low potential for lethality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. However, there is some concern that they may increase the risk of suicidality; this remains an area of significant controversy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/26/11690?source=see_link\">",
"     \"Selective serotonin reuptake inhibitor poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15736?source=see_link\">",
"     \"Effect of antidepressants on suicide risk in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All medications that are prescribed for the suicidal child must be monitored and any changes in behavior or side effects must be reported immediately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/6/13413?source=see_link\">",
"       \"Patient information: Depression in adolescents (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/21/29013?source=see_link\">",
"       \"Patient information: Depression treatment options for adolescents (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric health care providers can take the following actions to prevent suicide in children and adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38071/abstract/10,27\">",
"     10,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Know the risk factors for suicide in children and adolescents. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23834?source=see_link\">",
"       \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recognize the clinical presentations of and differential diagnoses for psychiatric disorders in children and adolescents. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5289?source=see_link\">",
"       \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Take active steps to identify children and adolescents at risk for suicide (eg, ask about suicidal thoughts and suicide risk factors during routine health care visits) and pursue early treatment for at-risk youth.",
"     </li>",
"     <li>",
"      Provide anticipatory guidance regarding the risks of access to firearms and other lethal means (eg, drugs, prescription medications).",
"     </li>",
"     <li>",
"      Be familiar with community, state, and national resources that are concerned with youth suicide (",
"      <a class=\"graphic graphic_table graphicRef69075 graphicRef78512 \" href=\"mobipreview.htm?32/26/33197\">",
"       table 4A-B",
"      </a>",
"      ), particularly local individuals and agencies that accept referrals in times of crisis.",
"     </li>",
"     <li>",
"      Provide support in times of crisis.",
"     </li>",
"     <li>",
"      Consult with mental health colleagues and coordinate care.",
"     </li>",
"     <li>",
"      Advocate eliminating barriers in public and private insurance programs for provision of quality mental health and substance use disorder treatments.",
"     </li>",
"     <li>",
"      Implement strategies to reduce the stigma associated with depression, substance abuse, and suicidal behavior and with seeking help for such problems.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/1\">",
"      Catallozzi M, Pletcher JR, Schwarz DF. Prevention of suicide in adolescents. Curr Opin Pediatr 2001; 13:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/2\">",
"      American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with suicidal behavior. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 2001; 40:24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/3\">",
"      Rudd MD, Berman AL, Joiner TE Jr, et al. Warning signs for suicide: theory, research, and clinical applications. Suicide Life Threat Behav 2006; 36:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/4\">",
"      Wintersteen MB, Diamond GS, Fein JA. Screening for suicide risk in the pediatric emergency and acute care setting. Curr Opin Pediatr 2007; 19:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/5\">",
"      Gould MS, Marrocco FA, Kleinman M, et al. Evaluating iatrogenic risk of youth suicide screening programs: a randomized controlled trial. JAMA 2005; 293:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/6\">",
"      Tishler CL, Reiss NS, Rhodes AR. Suicidal behavior in children younger than twelve: a diagnostic challenge for emergency department personnel. Acad Emerg Med 2007; 14:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/7\">",
"      Horowitz LM, Wang PS, Koocher GP, et al. Detecting suicide risk in a pediatric emergency department: development of a brief screening tool. Pediatrics 2001; 107:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/8\">",
"      Pfeffer CR. Diagnosis of childhood and adolescent suicidal behavior: unmet needs for suicide prevention. Biol Psychiatry 2001; 49:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/9\">",
"      Gould MS, Fisher P, Parides M, et al. Psychosocial risk factors of child and adolescent completed suicide. Arch Gen Psychiatry 1996; 53:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/10\">",
"      Shain BN, American Academy of Pediatrics Committee on Adolescence. Suicide and suicide attempts in adolescents. Pediatrics 2007; 120:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/11\">",
"      Borowsky IW, Ireland M, Resnick MD. Adolescent suicide attempts: risks and protectors. Pediatrics 2001; 107:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/12\">",
"      Press BR, Khan SA. Management of the suicidal child or adolescent in the emergency department. Curr Opin Pediatr 1997; 9:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/13\">",
"      Brent DA. The aftercare of adolescents with deliberate self-harm. J Child Psychol Psychiatry 1997; 38:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/14\">",
"      Range LM, Campbell C, Kovac SH, et al. No-suicide contracts: an overview and recommendations. Death Stud 2002; 26:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/15\">",
"      Simon RI. The suicide prevention contract: clinical, legal, and risk management issues. J Am Acad Psychiatry Law 1999; 27:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/16\">",
"      Kroll J. Use of no-suicide contracts by psychiatrists in Minnesota. Am J Psychiatry 2000; 157:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/17\">",
"      Kelly KT, Knudson MP. Are no-suicide contracts effective in preventing suicide in suicidal patients seen by primary care physicians? Arch Fam Med 2000; 9:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/18\">",
"      Rotheram-Borus MJ, Piacentini J, Van Rossem R, et al. Enhancing treatment adherence with a specialized emergency room program for adolescent suicide attempters. J Am Acad Child Adolesc Psychiatry 1996; 35:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/19\">",
"      Kennedy SP, Baraff LJ, Suddath RL, Asarnow JR. Emergency department management of suicidal adolescents. Ann Emerg Med 2004; 43:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/20\">",
"      Stewart C, Spicer M, Babl FE. Caring for adolescents with mental health problems: challenges in the emergency department. J Paediatr Child Health 2006; 42:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/21\">",
"      Jackson GH, Meyer A, Lippmann S. Wilson's disease. Psychiatric manifestations may be the clinical presentation. Postgrad Med 1994; 95:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/22\">",
"      Brent DA, Birmaher B. Clinical practice. Adolescent depression. N Engl J Med 2002; 347:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/23\">",
"      Dorfman DH, Kastner B. The use of restraint for pediatric psychiatric patients in emergency departments. Pediatr Emerg Care 2004; 20:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/24\">",
"      Sorrentino A. Chemical restraints for the agitated, violent, or psychotic pediatric patient in the emergency department: controversies and recommendations. Curr Opin Pediatr 2004; 16:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/25\">",
"      Schoenwald SK, Ward DM, Henggeler SW, Rowland MD. Multisystemic therapy versus hospitalization for crisis stabilization of youth: placement outcomes 4 months postreferral. Ment Health Serv Res 2000; 2:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/26\">",
"      Mourilhe P, Stokes PE. Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression. Drug Saf 1998; 18:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38071/abstract/27\">",
"      Mann JJ, Apter A, Bertolote J, et al. Suicide prevention strategies: a systematic review. JAMA 2005; 294:2064.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1230 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_11_38071=[""].join("\n");
var outline_f37_11_38071=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IDENTIFICATION OF SUICIDE RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Asking about suicide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intervention/referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EMERGENCY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      History and examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Psychiatric evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hospitalization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Involuntary hospitalization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Intensive home therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Outpatient therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/1230\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1230|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/13/24796\" title=\"table 1\">",
"      Suicide risk assessment1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/50/18220\" title=\"table 2\">",
"      Suicide risk assessment2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/33/44572\" title=\"table 3\">",
"      Suicide evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/62/35820\" title=\"table 4A\">",
"      Suicide resources A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/44/7884\" title=\"table 4B\">",
"      Suicide resources B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/12/7367?source=related_link\">",
"      Classification of trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/2/10281?source=related_link\">",
"      Confidentiality in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5289?source=related_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15736?source=related_link\">",
"      Effect of antidepressants on suicide risk in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/19000?source=related_link\">",
"      Guidelines for adolescent preventive services",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13114?source=related_link\">",
"      Management of acetaminophen (paracetamol) poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/6/13413?source=related_link\">",
"      Patient information: Depression in adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/21/29013?source=related_link\">",
"      Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19098?source=related_link\">",
"      Salicylate poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/26/11690?source=related_link\">",
"      Selective serotonin reuptake inhibitor poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23834?source=related_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_11_38072="Erythema nodosum - legs";
var content_f37_11_38072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76621%7EDERM%2F55744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76621%7EDERM%2F55744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema nodosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous nodules are present on the legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema nodosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous nodule is present on the lower leg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_11_38072=[""].join("\n");
var outline_f37_11_38072=null;
var title_f37_11_38073="Treatment of bronchiectasis in adults";
var content_f37_11_38073=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of bronchiectasis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/11/38073/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/11/38073/contributors\">",
"     Alan F Barker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/11/38073/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/11/38073/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/11/38073/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/11/38073/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/11/38073/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/11/38073/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchiectasis is a syndrome of chronic cough and daily viscid sputum production associated with airway dilatation and bronchial wall thickening. Multiple conditions are associated with the development of bronchiectasis, but all require an infectious insult plus impairment of drainage, airway obstruction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a defect in host defense.",
"   </p>",
"   <p>",
"    Treatment of bronchiectasis is aimed at controlling infection and improving bronchial hygiene. Surgical extirpation of affected areas may be useful in selected patients. Most of the information presented herein comes from descriptive series or anecdotal reports, rather than randomized clinical trials. In addition, some therapeutic techniques have been studied specifically in patients with cystic fibrosis, a cause of bronchiectasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of bronchiectasis will be reviewed here. The clinical manifestations and diagnosis of bronchiectasis and the treatment of cystic fibrosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=see_link\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/10/12458?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The British Thoracic Society has issued a statement for care of respiratory patients with bronchiectasis. Specialist referral and hospitalization guidelines are discussed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since infection plays a major role in causing and perpetuating bronchiectasis, reducing the microbial load and attendant mediators is a cornerstone of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/3\">",
"     3",
"    </a>",
"    ]. Antibiotics are used to treat an acute exacerbation and prevent recurrent infection by suppression or eradication of existing flora.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acute exacerbation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deciding when an acute exacerbation is occurring depends upon symptomatic changes rather than any specific laboratory feature. Acute bacterial infections are usually heralded by increased production of sputum that is more viscous with darker color, often accompanied by lassitude, shortness of breath, and pleuritic chest pain. Systemic complaints such as fever and chills are generally absent, and the plain chest radiograph rarely shows new infiltrates.",
"   </p>",
"   <p>",
"    The colonizing bacterial flora is slightly different from that seen in patients with chronic bronchitis. Frequently isolated pathogens include",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    ,",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    (especially mucoid types), and, less frequently,",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A fluoroquinolone is therefore a reasonable therapeutic option for ambulatory oral administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/6\">",
"     6",
"    </a>",
"    ]. The addition of inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    solution (TS) to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    was studied because of concerns regarding virulence and potential resistance of Pseudomonas. In a double-blind, multicenter trial, 53 patients with known Pseudomonas infection who were having exacerbations of bronchiectasis were randomly assigned to receive ciprofloxacin plus TS or ciprofloxacin plus placebo for two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/7\">",
"     7",
"    </a>",
"    ]. The addition of TS to ciprofloxacin did not improve clinical outcomes compared to ciprofloxacin alone, although there was a marked reduction of Pseudomonas density in the sputum of patients who received TS plus ciprofloxacin. Wheezing increased in the TS plus ciprofloxacin group. TS cannot be recommended alone or in combination with ciprofloxacin for acute exacerbations in bronchiectasis.",
"   </p>",
"   <p>",
"    The duration of therapy is not well defined, but a minimum of 7 to 10 days has become frequent practice. Sputum culture and sensitivity to help define antibiotic selection are indicated in patients who fail to respond to the initial antibiotic, or who have repeated symptomatic attacks over a short period of time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less clear and not well studied is the role of so-called preemptive, suppressive, or preventive antibiotic regimens. Examples of such regimens are listed in order of increasing complexity and expense.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strategy 1 &ndash; Daily oral antibiotic treatment, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (500 to 1500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in two to three divided doses) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/8\">",
"       8",
"      </a>",
"      ]. Alternatively, a similar antibiotic given for 7 to 14 days of each month.",
"     </li>",
"     <li>",
"      Strategy 2 &ndash; Daily or three times weekly use of a macrolide antibiotic, a modification of Strategy 1 that is efficacious in the management of cystic fibrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/9\">",
"       9",
"      </a>",
"      ]. The benefit of this approach was demonstrated in a double-blind trial that randomly assigned 19 patients with bronchiectasis to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      (500 mg, twice per day) or placebo for eight weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/10\">",
"       10",
"      </a>",
"      ]. Spirometric variables (forced vital capacity [FVC] and forced expiratory volume in 1 second [FEV",
"      <sub>",
"       1",
"      </sub>",
"      ]) improved and sputum volumes decreased in the erythromycin group, but not the placebo group. Sputum leukocyte density did not change significantly in either group.",
"      <br/>",
"      <br/>",
"      The role of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      in preventive therapy has also been examined [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. In the Effectiveness of Macrolides in patients with Bronchiectasis using Azithromycin to Control Exacerbations (EMBRACE) trial, 141 patients with at least one exacerbation of bronchiectasis in the prior year were randomly assigned to take azithromycin 500 mg or placebo, orally three times a week for six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/12\">",
"       12",
"      </a>",
"      ]. Azithromycin was associated with a decrease in exacerbations compared with placebo (RR 0.38, 95% CI 0.26&ndash;0.54). However, no significant difference was noted in lung function or quality of life.",
"      <br/>",
"      <br/>",
"      When used in this fashion, the effect of the macrolide antibiotic is not primarily antimicrobial. A variety of alternative mechanisms have been proposed to explain the observed benefit, including reduction of biofilms around virulent gram negative organisms such as Pseudomonas aeruginosa, retardation of neutrophilic influx, stabilization of nuclear and cellular membranes, and promotion of gastric emptying that may reduce potential for acid reflux. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H12#H12\">",
"       \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Macrolide antibiotics'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Some experts obtain sputum stains and cultures for nontuberculous mycobacterial (NTM) infection prior to initiating long-term azithromycin therapy. Preventive monotherapy with a macrolide antibiotic is NOT initiated if NTM are identified on culture. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H12#H12\">",
"       \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Macrolide antibiotics'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H7\">",
"       'Mycobacterium avium complex'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Strategy 3 &ndash; Aerosolization of an antibiotic. This technique has been investigated primarily when",
"      <em>",
"       Pseudomonas aeruginosa",
"      </em>",
"      is present in the respiratory secretions of patients with cystic fibrosis. In the largest trial, 520 patients with cystic fibrosis who had",
"      <em>",
"       Pseudomonas aeruginosa",
"      </em>",
"      in their respiratory secretions were randomly assigned to receive inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      (300 mg, twice daily) or inhaled placebo every other month for six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/13\">",
"       13",
"      </a>",
"      ]. The inhaled tobramycin group had a 100-fold reduction in sputum Pseudomonas density, improved FEV",
"      <sub>",
"       1",
"      </sub>",
"      , and decreased hospitalizations compared to the placebo group. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=see_link&amp;anchor=H16#H16\">",
"       \"Cystic fibrosis: Antibiotic therapy for lung disease\", section on 'Aerosolized antibiotics'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The use of aerosolized antibiotics has also been studied in patients with bronchiectasis in the absence of cystic fibrosis (CF) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/14-17\">",
"       14-17",
"      </a>",
"      ]. One trial randomly assigned 74 patients with non-CF bronchiectasis and bacteriologic evidence of",
"      <em>",
"       Pseudomonas aeruginosa",
"      </em>",
"      infection to receive aerosolized tobramycin (300 mg, twice daily) or aerosolized placebo for 28 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/14\">",
"       14",
"      </a>",
"      ]. Patients in the treatment group demonstrated a 10,000-fold reduction in Pseudomonas density, but no change in FEV",
"      <sub>",
"       1",
"      </sub>",
"      as compared to controls.",
"      <br/>",
"      <br/>",
"      In a 6 month double blind crossover study of aerosol tobramycin in 30 patients, there was no change in exacerbation rate, but the number of hospitalizations and duration of hospital stay were reduced during the tobramycin phase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/18\">",
"       18",
"      </a>",
"      ]. Of concern, four patients in the tobramycin group and one in the placebo group died during the study.",
"      <br/>",
"      <br/>",
"      In a smaller uncontrolled study, aerosolized tobramycin (300 mg, twice daily) was administered to 41 patients with non-CF bronchiectasis and a history of Pseudomonas infection; the protocol alternated two weeks of treatment with two weeks without therapy for a total of 12 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/15\">",
"       15",
"      </a>",
"      ]. Treatment was associated with a decrease in symptoms and improvements in health-related quality of life (QOL). However, 10 of 41 patients (24 percent) were unable to complete the protocol because of side effects (cough, wheezing or worsened dyspnea), and two of the patients who completed the trial acquired tobramycin-resistant Pseudomonas species.",
"      <br/>",
"      <br/>",
"      Aerosolized",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      , prepared by diluting the intravenous preparation with saline, was assessed in 58 patients with non-CF bronchiectasis, who were randomly assigned to use nebulized gentamicin 80 mg twice daily or normal saline placebo for a year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/17\">",
"       17",
"      </a>",
"      ]. The primary endpoint of reduction in sputum bacterial density (almost a 3 log10",
"      <span class=\"nowrap\">",
"       cfu/mL",
"      </span>",
"      reduction) was achieved in the gentamicin cohort as compared to no reduction in the saline group. Thirty-one percent of the gentamicin cohort had complete eradication of Pseudomonas at the end of 12 months. Favorable secondary endpoints in subjects taking gentamicin included reduction in exacerbations and improved patient outcomes by analysis of two questionnaires. However, no differences were seen in the 24 hour sputum volume or in spirometric parameters. In addition, the sputum bacterial density was no longer different from control at the three month follow-up visit.",
"      <br/>",
"      <br/>",
"      Other inhaled antibiotics are under investigation including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      and both dry powder and dual-release (contains free and liposomal drug) preparations of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/19-21\">",
"       19-21",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In summary, aerosol antibiotics may play a role in the management of some patients with non-CF bronchiectasis and Pseudomonas infection. Bronchospasm may occur in some patients. No agent is approved for this purpose by the US FDA.",
"     </li>",
"     <li>",
"      Strategy 4 &ndash; Intermittent intravenous antibiotics. This strategy should be reserved for patients with resistant organisms (such as Pseudomonas) or in preparation for major surgery, including resection of a bronchiectatic region of lung or other procedures during which pulmonary function may be compromised.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neither Strategies 1 nor 2 have been tested in long-term studies, but seem reasonable to suppress infecting organisms in selected patients. The final two strategies are expensive and require extra equipment and personnel. These should be reserved for individual patients failing one of the first two regimens. In addition, patients treated with inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    should be assessed for medication-related side effects and the development of resistant organisms.",
"   </p>",
"   <p>",
"    Clinical trials of preemptive strategies have several problems, including the requirement for a large number of patients, difficulty in providing an appropriate placebo, need for long-term follow-up (six or more months), and lack of suitable end points. The St. George's Respiratory Questionnaire and the Leicester Cough Questionnaire have been validated as measures of respiratory health in bronchiectasis, and may become tools for clinical studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. In a pilot study, a modification of the cystic fibrosis QOL questionnaire has shown strong internal validity as an index of Patient Reported Outcomes (PRO), an increasingly accepted outcome measure by regulatory authorities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROBLEMATIC PATHOGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three colonizing organisms that contribute to symptomatic episodes are particularly problematic and difficult to eradicate:",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    , Mycobacterium avium complex (MAC), and Aspergillus species.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pseudomonas",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    has a propensity to persist in damaged (eg, bronchiectatic) airways. This is due to its ability to produce virulence factors and to modulate immune defenses with quorum signaling and biofilm production. Pseudomonas can also interact adversely and directly with the airway epithelial surface and the cystic fibrosis conductance regulator (CFTR) protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39095?source=see_link&amp;anchor=H3#H3\">",
"     \"Cystic fibrosis: Genetics and pathogenesis\", section on 'The normal CFTR gene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients colonized with",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    have reduced quality of life indices, more extensive bronchiectasis on CT, accelerated decline in pulmonary function, and increased number of hospitalizations, compared to patients colonized with",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27145?source=see_link\">",
"     \"Epidemiology and pathogenesis of Pseudomonas aeruginosa infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    and other quinolones currently are the only oral agents effective against",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    . However, resistance often develops after one to two treatment cycles. Intravenous antibiotics are often needed when Pseudomonas causes repeated symptomatic episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31494?source=see_link\">",
"     \"Pseudomonas aeruginosa pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mycobacterium avium complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycobacterium avium complex (MAC) refers to infections caused by one of two nontuberculous mycobacterial species, either M. avium or M. intracellulare. MAC and other nontuberculous mycobacteria are often harbored in damaged lung tissue and bronchiectatic airways. A detailed discussion about the treatment of MAC and other nontuberculous mycobacteria in the lung is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=see_link\">",
"     \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5687?source=see_link\">",
"     \"Microbiology of nontuberculous mycobacteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Aspergillus species",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    is the cornerstone of therapy for patients with allergic bronchopulmonary aspergillosis; they may also benefit from additional therapy with a prolonged course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Therapy initiated prior to the development of bronchiectasis may prevent or delay permanent airway destruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     BRONCHIAL HYGIENE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchiectasis is the prototypical disease for which secretion loosening or thinning combined with enhanced removal techniques should be salutary, although large population and long-term studies of efficacy are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/32\">",
"     32",
"    </a>",
"    ]. Bronchial hygiene is particularly important as tenacious secretions and mucous plugs are frequently present. Potential approaches include hydration, nebulization with saline solutions and mucolytic agents, mechanical techniques, bronchodilators, and antiinflammatory therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34648?source=see_link\">",
"     \"Role of mucoactive agents in the treatment of COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hydration and mucus clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of euvolemia with oral liquids is a logical, although unstudied, approach to avoiding inspissation of secretions. There is no evidence that hydration beyond euvolemia provides any benefit.",
"   </p>",
"   <p>",
"    Nebulized hyperosmolar agents, including hypertonic (7 percent) saline and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , have been studied as mucokinetic therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/33\">",
"     33",
"    </a>",
"    ]. Their mechanism of action is probably related to improved mucus rheology, increased ciliary motility, and enhanced cough clearance. Another possibility, suggested by in vitro data, is that low mucus salinity rather than under hydration contributes to mucus retention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized double blind trial of aerosolized dry powder",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    350 mg (186 patients) versus placebo (95 patients) twice daily for three months showed significant improvements in the St. George's Respiratory Questionnaire, longer time to first antibiotic use, and less antibiotic use in the mannitol group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/35\">",
"     35",
"    </a>",
"    ]. Aerosol dry powder mannitol is not an approved drug in the United States.",
"   </p>",
"   <p>",
"    Studies of mucolytic agents that cleave disulfide bonds in glycoproteins or breakdown DNA have yielded variable results. Studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    , for example, have not found clear benefit among patients with cystic fibrosis (CF) and there are no well-designed studies in non-CF-related bronchiectasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/36\">",
"     36",
"    </a>",
"    ]. Aerosolized recombinant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/13/29908?source=see_link\">",
"     DNase",
"    </a>",
"    I (dornase alpha, a deoxyribonuclease enzyme), which breaks down DNA (a major gelatinous product of neutrophils), improves pulmonary function (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ), and reduces hospitalizations in CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/37\">",
"     37",
"    </a>",
"    ], but is not effective in non-CF-related bronchiectasis and is potentially harmful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chest physiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous chest physiotherapy techniques and devices exist to mechanically loosen viscid secretions; the most popular are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef78373 \" href=\"mobipreview.htm?34/52/35659\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Some of the techniques and devices have been popularized by patients and clinicians, despite a paucity of good data.",
"   </p>",
"   <p>",
"    Most studies have been small, uncontrolled, short-term, and without patient-important endpoints. However, one trial assessed the efficacy of an oscillatory positive expiratory pressure (PEP) device used for three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/41\">",
"     41",
"    </a>",
"    ]. Twenty patients who were not practicing chest physiotherapy were randomly assigned to PEP twice daily versus no device, in a crossover design. The primary endpoint was the Leicester Cough Questionnaire (LCQ); sputum volume, spirometry, exercise capacity, exacerbation frequency, and sputum microbiology were also assessed. After three months of using oscillatory PEP, a significant improvement in the LCQ, a reduction in sputum volume, and an improved exercise capacity were noted. No change was found in spirometric parameters, exacerbation frequency, or sputum microbiology.",
"   </p>",
"   <p>",
"    The choice of a technique or device should be based upon patient comfort, cost, and the patient's ability to use the technique or device with minimal interference to their lifestyle and minimal detriment to coexisting medical conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H9#H9\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Chest physiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     BRONCHODILATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway reactivity, presumably due to transmural inflammation, is often present in patients with bronchiectasis. Aerosol bronchodilator therapy, as used in chronic bronchitis, may be appropriate but has not been studied rigorously in patients with bronchiectasis. When deciding whether to prescribe a bronchodilator for bronchiectasis, we usually assess airflow obstruction on spirometry before and after bronchodilator. For those patients with bronchodilator reversibility, we typically initiate a trial of a short-acting beta agonist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/2\">",
"     2",
"    </a>",
"    ]. If symptoms improve on therapy, either a short or long-acting bronchodilator is continued. &nbsp;",
"   </p>",
"   <p>",
"    In a 12 month randomized trial of 40 patients with noncystic fibrosis bronchiectasis, the combination of inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    640",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    was compared with inhaled budesonide 1600",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/42\">",
"     42",
"    </a>",
"    ]. The formoterol group experienced improved dyspnea, coughing, and health related quality of life based on a HRQL questionnaire (SGRQ-Spanish version) without alteration in sputum pathogens or an increase in adverse effects. Further study is needed before long-acting beta-adrenergic agonists are used routinely in patients with bronchiectasis, but without wheezing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ANTIINFLAMMATORY MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since inflammation and neutrophilic mediator release play a major role in bronchiectasis, antiinflammatory agents such as oral or inhaled glucocorticoids might theoretically be beneficial. However, there are no large randomized controlled trials upon which to make recommendations regarding the efficacy of oral glucocorticoids in the treatment of stable or acute bronchiectasis. We reserve systemic glucocorticoids for acute exacerbations of bronchiectasis that are accompanied by wheezing, as systemic glucocorticoids depress host immunity, promote increased bacterial and fungal colonization, and may perpetuate infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, oral glucocorticoids have other significant adverse effects that are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several small trials suggest that inhaled glucocorticoids improve lung function and dyspnea, while reducing cough, sputum production, and the need for beta-agonist rescue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. However, inhaled glucocorticoids have not been shown to reduce the frequency of exacerbations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of inhaled glucocorticoids was examined in a trial that randomly assigned 93 patients with bronchiectasis to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    250 mcg twice daily, fluticasone 500 mcg twice daily, or no inhaled glucocorticoid for six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/47\">",
"     47",
"    </a>",
"    ]. The group that received fluticasone 500 mcg twice daily had improvement in dyspnea (measured by a symptom score and the St. George's Respiratory Questionnaire), reduced sputum production, and required less beta-agonist rescue, compared to baseline. There was no change in pulmonary function or the exacerbation rate. Important limitations of this trial include the absence of a placebo group, short duration (which limits its ability to detect a change in the frequency of exacerbations), and enrollment of patients with COPD.",
"   </p>",
"   <p>",
"    Current evidence is insufficient to support routine inhaled glucocorticoid therapy for patients with bronchiectasis but without concomitant asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/2\">",
"     2",
"    </a>",
"    ]. Inhaled glucocorticoids have potential adverse effects to keep in mind. As an example, patients with bronchiectasis may have underlying adrenal insufficiency that can be exacerbated by inhaled glucocorticoid use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/48\">",
"     48",
"    </a>",
"    ]. Adverse effects of inhaled glucocorticoids are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=see_link\">",
"     \"Major side effects of inhaled glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     GASTROESOPHAGEAL REFLUX",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is emerging concern that gastroesophageal reflux and bronchiectasis are associated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/49\">",
"     49",
"    </a>",
"    ]. As a result, gastric acid suppression should be considered in most patients. Either an H2 blocker or a proton pump inhibitor can be used. The role of diagnostic testing (eg, esophageal pH monitoring, manometry, esophagram, or upper endoscopy) is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PULMONARY REHABILITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary rehabilitation is efficacious in COPD. In a trial of 32 patients with bronchiectasis, an eight week exercise rehabilitation program improved the distance walked during a walk test and endurance capacity, compared to a control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/50\">",
"     50",
"    </a>",
"    ]. The addition of specific inspiratory muscle training extended the improvement in exercise capacity another three months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of impaired defense mechanisms and recurrent infection often results in bronchiectasis becoming a diffuse lung disease with little opportunity for surgical cure. Nevertheless, there is a role for surgery in some patients. Goals are more conservative, with less reliance on cure or elimination of all areas of bronchiectasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2092206\">",
"    <span class=\"h2\">",
"     Resection of bronchiectatic lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immediate goal of surgical extirpation includes removal of the most involved segments or lobes with preservation of nonsuppurative or nonbleeding areas. Middle and lower lobe resections are most often performed. The superior segment of the lower lobe may be involved to a lesser extent and can frequently be salvaged when considering lower lobe resection. Surgical intervention is often combined with an aggressive antibiotic and bronchial hygiene regimen to reduce bacterial infection and allow better drainage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Major indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major indications and goals for surgery in bronchiectasis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Removal of destroyed lung partially obstructed by a tumor or the residue of a foreign body",
"     </li>",
"     <li>",
"      Reduction in acute infective episodes",
"     </li>",
"     <li>",
"      Reduction in overwhelming purulent and viscid sputum production",
"     </li>",
"     <li>",
"      Elimination of bronchiectatic airways subject to uncontrolled hemorrhage",
"     </li>",
"     <li>",
"      Removal of an area suspected of harboring resistant organisms such as MAC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/51\">",
"       51",
"      </a>",
"      ] or multidrug resistant tuberculosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2093471\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical case series have shown low operative mortality (&lt;2 percent) and resolution or improvement of symptoms in the majority of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/50,53-56\">",
"     50,53-56",
"    </a>",
"    ]. The following studies illustrate typical outcomes that follow surgical resection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest study from the past two decades, 790 Chinese patients (mean age 47 years) were followed for a mean of four years following lung resection (segmentectomy, lobectomy, pneumonectomy) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/53\">",
"       53",
"      </a>",
"      ]. Mortality at 30 days was 1.1 percent. Seventy-five percent of patients became asymptomatic or were improved, while 15 percent were unimproved or worse.",
"     </li>",
"     <li>",
"      In a study from the United States, 134 patients (mean age 48 years) were followed for a mean of six years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/54\">",
"       54",
"      </a>",
"      ]. Mortality was 2 percent and 89 percent of patients improved.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Postoperative complications include empyema, hemorrhage, prolonged air leak, and poorly expanding remaining lung due to persistent atelectasis or suppuration. In selected patients, video-assisted thoracoscopic surgery (VATS) segmentectomy or lobectomy may be possible and allow fewer complications and shorter hospitalizations. Pleural adhesions may require conversion to thoracotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Management of hemoptysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent surgery is occasionally required for the management of intractable or life-threatening hemoptysis (&gt;600",
"    <span class=\"nowrap\">",
"     mL/day)",
"    </span>",
"    due to bronchiectasis. Bleeding in bronchiectasis is often associated with acute infective episodes and is produced by injury to superficial mucosal neovascular bronchial arterioles. Bronchoscopy and chest CT are complementary diagnostic tools to localize the bleeding to a lobe or segment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/57\">",
"     57",
"    </a>",
"    ]. Once the site of bleeding is identified, bronchoscopic techniques such as balloon tamponade, topical application of a vasoconstrictive or coagulant agent, laser therapy, electrocautery, argon plasma coagulation, and cryotherapy may be able to stop the bleeding. The evaluation and management of massive hemoptysis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=see_link\">",
"     \"Massive hemoptysis: Initial management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=see_link&amp;anchor=H7235390#H7235390\">",
"     \"Massive hemoptysis: Initial management\", section on 'Non-surgical'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If bronchoscopic techniques to control bleeding are unsuccessful or are not available, the next step is usually arteriographic embolization of bleeding sites (typically from a bronchial artery) by an interventional radiology service. Bronchial artery embolization successfully stops pulmonary hemorrhage in more than 85 percent of attempted embolizations. Bronchial artery embolization preserves lung tissue and often eliminates the need for surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/58\">",
"     58",
"    </a>",
"    ]. However, if embolization is unsuccessful and bleeding persists, surgical resection may be necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=see_link&amp;anchor=H4655186#H4655186\">",
"     \"Massive hemoptysis: Initial management\", section on 'Control the bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2092260\">",
"    <span class=\"h2\">",
"     Airway stabilization for tracheobronchomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with tracheobronchomegaly (eg, Mounier-Kuhn Syndrome), tracheal stabilizing procedures such as proximal stents or tracheobronchoplasty may enhance clearance of airway secretions and improve pulmonary function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18088?source=see_link&amp;anchor=H16#H16\">",
"     \"Tracheomalacia and tracheobronchomalacia in adults\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lung transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suppurative lung disease were initially considered poor candidates for lung transplantation due to the potential persistence of infection that might worsen during prolonged immunosuppression. However, with bilateral lung transplantation, the survival advantage of transplantation is now thought to be comparable to that of other diagnostic groups. As an example, 54 patients with bronchiectasis underwent bilateral lung transplantation in the United Kingdom between 1997 and 2007. The mean age was 54 and the median transplant list waiting time was 309 days. The median survival time for transplant recipients was 8 years. In comparison, 59 patients died while on the waiting list [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     IMMUNIZATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited regarding immunization guidelines for individuals with chronic respiratory diseases. Seasonal influenza vaccine is typically administered annually to patients with bronchiectasis, as for other chronic diseases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regarding the 23 valent pneumococcal vaccine, in a prospective randomized study of 167 adults with chronic respiratory diseases including 20 with probable bronchiectasis, the group receiving both influenza and pneumococcal vaccines had significantly reduced numbers of acute infectious exacerbations during the first, but not second year of the study as compared to the group receiving the influenza vaccine alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/61\">",
"     61",
"    </a>",
"    ]. Although the data are limited, pneumococcal vaccine is typically given to patients with bronchiectasis, as recommended for patients with chronic diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long term outcome studies of bronchiectasis are limited. However, a few studies have examined the frequency of exacerbations, hospitalizations, and mortality and the rate of lung function decline among patients with bronchiectasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/27,38,63-66\">",
"     27,38,63-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exacerbations &ndash; In the aerosol recombinant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/13/29908?source=see_link\">",
"       DNAse",
"      </a>",
"      study, 349 patients experienced an average of one pulmonary exacerbation every six to eight months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/38\">",
"       38",
"      </a>",
"      ]. One-third of these episodes were severe enough to require hospitalization.",
"     </li>",
"     <li>",
"      Hospitalization and mortality &ndash; A retrospective cohort study identified 842 patients with bronchiectasis from the National Hospital Discharge Registry in Finland and followed those patients for 8 to 12.9 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/63\">",
"       63",
"      </a>",
"      ]. The number of hospitalizations per patient varied widely (range 1 to 51), with a mean of 2.2 episodes per patient. There were 239 deaths (28 percent of patients), mostly related to respiratory complications.",
"      <br/>",
"      <br/>",
"      There is limited information regarding the prognosis of patients with bronchiectasis and respiratory insufficiency admitted to an intensive care unit. Two retrospective series assessed outcomes of patients with bronchiectasis admitted to an ICU for respiratory failure for the first time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/64,67\">",
"       64,67",
"      </a>",
"      ]. A report of 48 patients from France found 19 percent mortality in the ICU and 40 percent mortality at one year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/64\">",
"       64",
"      </a>",
"      ]. In a series of 57 patients from Singapore, an overall hospital mortality of 26 percent was reported with no difference whether the patients received non-invasive ventilation or intubation with mechanical ventilation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/67\">",
"       67",
"      </a>",
"      ]. Severe hypoxemia and higher APACHE II scores were worse prognostic factors. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=see_link\">",
"       \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lung function decline &ndash; Patients with bronchiectasis have a mean annual decline in FEV",
"      <sub>",
"       1",
"      </sub>",
"      of 50 to 55 mL per year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/27\">",
"       27",
"      </a>",
"      ]. This is greater than normal individuals (20 to 30 mL per year) and similar to patients with COPD (approximately 60 mL per year). Among patients with bronchiectasis, the decline in FEV",
"      <sub>",
"       1",
"      </sub>",
"      is most accelerated when Pseudomonas colonization, frequent exacerbations, or increased inflammatory markers (eg, C-reactive protein) exist.",
"     </li>",
"     <li>",
"      Pulmonary vascular disease &ndash; An observational study evaluated 94 patients with bronchiectasis using echocardiography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/65\">",
"       65",
"      </a>",
"      ]. There was evidence of pulmonary hypertension (defined as an estimated systolic pulmonary artery pressure &gt;40 mmHg) in 33 percent of patients and right ventricular systolic dysfunction in 13 percent. Both abnormalities were more common among patients with cystic bronchiectasis. Right ventricular dysfunction correlated with a low forced expiratory volume in one second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ), low diffusing capacity of carbon monoxide (DLCO), hypercarbia, and hypoxemia. Only 15 percent of patients had evidence of left ventricular dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods for noninvasive detection of tissue injury and impending or existing bronchiectasis are being sought. Bronchoalveolar lavage, while helpful diagnostically for some respiratory diseases, is probably too invasive for ongoing management of bronchiectasis. Exhaled breath condensates (for H",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    and NO) require specialized equipment and preliminary results have been conflicting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7416?source=see_link&amp;anchor=H11#H11\">",
"     \"Exhaled nitric oxide analysis\", section on 'Bronchiectasis, cystic fibrosis, and sarcoidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Analysis of induced sputum for inflammatory cell constituents and biomarkers (eg, 8-isoprostane) is an emerging methodology that may hold promise for assessing disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/68\">",
"     68",
"    </a>",
"    ]. Measuring sputum biomarkers with high throughput technology is another possible method for quantifying inflammation in airway diseases including bronchiectasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38073/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/25/39314?source=see_link\">",
"       \"Patient information: Bronchiectasis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchiectasis is a syndrome of chronic cough and daily viscid sputum production associated with airway dilatation and bronchial wall thickening. Exacerbations are usually caused by acute bacterial infections. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute exacerbation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For outpatients with an acute exacerbation and no history of recurrent exacerbations, we suggest initiation of a fluoroquinolone antibiotic, rather than an alternative oral antibiotic (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute exacerbation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For hospitalized patients with an acute exacerbation, we suggest initiation of two intravenous antibiotics with efficacy for Pseudomonas (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The antibiotics should have different mechanisms of killing. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute exacerbation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients (outpatients and inpatients) with an acute exacerbation and a history of recurrent exacerbations, we suggest the initial antibiotic choice be tailored to prior sputum cultures and sensitivities, rather than chosen empirically (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute exacerbation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with an acute exacerbation, we suggest at least seven to ten days of antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute exacerbation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have recurrent exacerbations, we suggest preventive antibiotics, rather than waiting until an exacerbation occurs to initiate antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Our threshold for the initiation of preventive antibiotics is three or more exacerbations within one year. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that all patients with bronchiectasis receive chest physiotherapy (",
"      <a class=\"graphic graphic_table graphicRef78373 \" href=\"mobipreview.htm?34/52/35659\">",
"       table 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Chest physiotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not using inhaled glucocorticoids for patients with bronchiectasis except in the presence of distressing wheeze and cough (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Systemic glucocorticoids should be reserved for acute exacerbations and should accompany antibacterial therapy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Antiinflammatory medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with non-cystic fibrosis-related bronchiectasis, we recommend NOT using dornase (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/13/29908?source=see_link\">",
"       DNAse",
"      </a>",
"      ) as a mucolytic agent (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hydration and mucus clearance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are insufficient data to advocate routine use of bronchodilators or pulmonary rehabilitation in patients with bronchiectasis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hydration and mucus clearance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Bronchodilators'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Pulmonary rehabilitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with life-threatening hemoptysis due to bronchiectasis, we suggest bronchial artery embolization rather than surgery, if an interventional radiology service is available (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Surgical therapy is appropriate if bronchial artery embolization fails or cannot be attempted in a timely fashion. (See",
"      <a class=\"local\" href=\"#H2092206\">",
"       'Resection of bronchiectatic lung'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical extirpation and lung transplantation should be considered on a case-by-case basis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Lung transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/1\">",
"      Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/2\">",
"      Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65 Suppl 1:i1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/3\">",
"      Watt AP, Brown V, Courtney J, et al. Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis. Thorax 2004; 59:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/4\">",
"      Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/5\">",
"      Angrill J, Agust&iacute; C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/6\">",
"      Tsang KW, Chan WM, Ho PL, et al. A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis. Eur Respir J 1999; 14:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/7\">",
"      Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006; 130:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/8\">",
"      Rayner CF, Tillotson G, Cole PJ, Wilson R. Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis. J Antimicrob Chemother 1994; 34:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/9\">",
"      Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/10\">",
"      Tsang KW, Ho PI, Chan KN, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999; 13:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/11\">",
"      Anwar GA, Bourke SC, Afolabi G, et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008; 102:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/12\">",
"      Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/13\">",
"      Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/14\">",
"      Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/15\">",
"      Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005; 127:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/16\">",
"      Lin HC, Cheng HF, Wang CH, et al. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Am J Respir Crit Care Med 1997; 155:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/17\">",
"      Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/18\">",
"      Drobnic ME, Su&ntilde;&eacute; P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005; 39:39.",
"     </a>",
"    </li>",
"    <li>",
"     Serisier DJ, Thompson PJ, Greville H, et al. Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non-cystic fibrosis(CF) bronchiectasis(BE). Presented annual congress European Respiratory Society, September 26, 2011, Amsterdam.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/20\">",
"      Quittner,A, Salathe, M, Barker A, et al. National Validation of a patient-reported outcome measure for bronchiectasis: psychometric results on the QOL-B. Am J Respir Crit Care Med 2010; 181:A5793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/21\">",
"      Wilson R, Welte T, Polverino E, et al. Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/22\">",
"      Wilson CB, Jones PW, O'Leary CJ, et al. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997; 156:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/23\">",
"      Chan SL, Chan-Yeung MM, Ooi GC, et al. Validation of the Hong Kong Chinese version of the St. George Respiratory Questionnaire in patients with bronchiectasis. Chest 2002; 122:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/24\">",
"      Murray MP, Turnbull K, MacQuarrie S, et al. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J 2009; 34:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/25\">",
"      Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005; 171:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/26\">",
"      Wilson CB, Jones PW, O'Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997; 10:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/27\">",
"      Mart&iacute;nez-Garc&iacute;a MA, Soler-Catalu&ntilde;a JJ, Perpi&ntilde;&aacute;-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007; 132:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/28\">",
"      Murray MP, Turnbull K, Macquarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009; 33:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/29\">",
"      Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/30\">",
"      Wark PA, Hensley MJ, Saltos N, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 2003; 111:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/31\">",
"      Kumar R. Mild, moderate, and severe forms of allergic bronchopulmonary aspergillosis: a clinical and serologic evaluation. Chest 2003; 124:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/32\">",
"      McCool FD, Rosen MJ. Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:250S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/33\">",
"      Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011; 105:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/34\">",
"      Wills PJ, Hall RL, Chan W, Cole PJ. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. J Clin Invest 1997; 99:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/35\">",
"      Bilton, D, Daviskas, E, Jacques, A, et al. A randomized, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis. Am J Respir Crit Care Med 2009; 179:A3221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/36\">",
"      Nash EF, Stephenson A, Ratjen F, Tullis E. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev 2009; :CD007168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/37\">",
"      Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/38\">",
"      O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998; 113:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/39\">",
"      Hess DR. Airway clearance: physiology, pharmacology, techniques, and practice. Respir Care 2007; 52:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/40\">",
"      Bott J, Blumenthal S, Buxton M, et al. Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patient. Thorax 2009; 64 Suppl 1:i1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/41\">",
"      Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009; 34:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/42\">",
"      Mart&iacute;nez-Garc&iacute;a M&Aacute;, Soler-Catalu&ntilde;a JJ, Catal&aacute;n-Serra P, et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest 2012; 141:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/43\">",
"      Elborn JS, Johnston B, Allen F, et al. Inhaled steroids in patients with bronchiectasis. Respir Med 1992; 86:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/44\">",
"      Tsang KW, Ho PL, Lam WK, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med 1998; 158:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/45\">",
"      Kharitonov SA, Wells AU, O'Connor BJ, et al. Elevated levels of exhaled nitric oxide in bronchiectasis. Am J Respir Crit Care Med 1995; 151:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/46\">",
"      Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005; 60:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/47\">",
"      Mart&iacute;nez-Garc&iacute;a MA, Perpi&ntilde;&aacute;-Tordera M, Rom&aacute;n-S&aacute;nchez P, Soler-Catalu&ntilde;a JJ. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med 2006; 100:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/48\">",
"      Holme J, Tomlinson JW, Stockley RA, et al. Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. Eur Respir J 2008; 32:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/49\">",
"      Tsang KW, Lam WK, Kwok E, et al. Helicobacter pylori and upper gastrointestinal symptoms in bronchiectasis. Eur Respir J 1999; 14:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/50\">",
"      Newall C, Stockley RA, Hill SL. Exercise training and inspiratory muscle training in patients with bronchiectasis. Thorax 2005; 60:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/51\">",
"      Pomerantz M, Denton JR, Huitt GA, et al. Resection of the right middle lobe and lingula for mycobacterial infection. Ann Thorac Surg 1996; 62:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/52\">",
"      Watanabe M, Hasegawa N, Ishizaka A, et al. Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones. Ann Thorac Surg 2006; 81:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/53\">",
"      Zhang P, Jiang G, Ding J, et al. Surgical treatment of bronchiectasis: a retrospective analysis of 790 patients. Ann Thorac Surg 2010; 90:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/54\">",
"      Agasthian T, Deschamps C, Trastek VF, et al. Surgical management of bronchiectasis. Ann Thorac Surg 1996; 62:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/55\">",
"      Mitchell JD, Yu JA, Bishop A, et al. Thoracoscopic lobectomy and segmentectomy for infectious lung disease. Ann Thorac Surg 2012; 93:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/56\">",
"      Balkanli K, Gen&ccedil; O, Dakak M, et al. Surgical management of bronchiectasis: analysis and short-term results in 238 patients. Eur J Cardiothorac Surg 2003; 24:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/57\">",
"      McGuinness G, Beacher JR, Harkin TJ, et al. Hemoptysis: prospective high-resolution CT/bronchoscopic correlation. Chest 1994; 105:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/58\">",
"      Yoon W, Kim JK, Kim YH, et al. Bronchial and nonbronchial systemic artery embolization for life-threatening hemoptysis: a comprehensive review. Radiographics 2002; 22:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/59\">",
"      Odell DD, Shah A, Gangadharan SP, et al. Airway stenting and tracheobronchoplasty improve respiratory symptoms in Mounier-Kuhn syndrome. Chest 2011; 140:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/60\">",
"      Titman A, Rogers CA, Bonser RS, et al. Disease-specific survival benefit of lung transplantation in adults: a national cohort study. Am J Transplant 2009; 9:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/61\">",
"      Furumoto A, Ohkusa Y, Chen M, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008; 26:4284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/62\">",
"      Chang CC, Singleton RJ, Morris PS, Chang AB. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev 2009; :CD006316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/63\">",
"      Keistinen T, S&auml;yn&auml;j&auml;kangas O, Tuuponen T, Kivel&auml; SL. Bronchiectasis: an orphan disease with a poorly-understood prognosis. Eur Respir J 1997; 10:2784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/64\">",
"      Dupont M, Gacouin A, Lena H, et al. Survival of patients with bronchiectasis after the first ICU stay for respiratory failure. Chest 2004; 125:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/65\">",
"      Alzeer AH, Al-Mobeirek AF, Al-Otair HA, et al. Right and left ventricular function and pulmonary artery pressure in patients with bronchiectasis. Chest 2008; 133:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/66\">",
"      Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009; 34:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/67\">",
"      Phua J, Ang YL, See KC, et al. Noninvasive and invasive ventilation in acute respiratory failure associated with bronchiectasis. Intensive Care Med 2010; 36:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/68\">",
"      Wood LG, Garg ML, Simpson JL, et al. Induced sputum 8-isoprostane concentrations in inflammatory airway diseases. Am J Respir Crit Care Med 2005; 171:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38073/abstract/69\">",
"      Gray RD, MacGregor G, Noble D, et al. Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med 2008; 178:444.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1435 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-7D04F74F15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_11_38073=[""].join("\n");
var outline_f37_11_38073=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acute exacerbation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROBLEMATIC PATHOGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pseudomonas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mycobacterium avium complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Aspergillus species",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      BRONCHIAL HYGIENE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hydration and mucus clearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chest physiotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      BRONCHODILATORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ANTIINFLAMMATORY MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      GASTROESOPHAGEAL REFLUX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PULMONARY REHABILITATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2092206\">",
"      Resection of bronchiectatic lung",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Major indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2093471\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Management of hemoptysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2092260\">",
"      Airway stabilization for tracheobronchomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      IMMUNIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1435\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1435|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/52/35659\" title=\"table 1\">",
"      Secretion clearance methods",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=related_link\">",
"      Cystic fibrosis: Antibiotic therapy for lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39095?source=related_link\">",
"      Cystic fibrosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27145?source=related_link\">",
"      Epidemiology and pathogenesis of Pseudomonas aeruginosa infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7416?source=related_link\">",
"      Exhaled nitric oxide analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5687?source=related_link\">",
"      Microbiology of nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/25/39314?source=related_link\">",
"      Patient information: Bronchiectasis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31494?source=related_link\">",
"      Pseudomonas aeruginosa pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34648?source=related_link\">",
"      Role of mucoactive agents in the treatment of COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18088?source=related_link\">",
"      Tracheomalacia and tracheobronchomalacia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_11_38074="Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids";
var content_f37_11_38074=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/11/38074/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/11/38074/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/11/38074/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/11/38074/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/11/38074/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/11/38074/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/11/38074/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis is a multisystem disease of unknown etiology characterized by tissue infiltration with noncaseating granulomas. The granulomas may occur in any organ, but the most frequently affected sites are the lungs, lymph nodes, skin, eyes, and liver. Patients with pulmonary sarcoidosis typically present without symptoms, but with an abnormal chest radiograph obtained for an unrelated reason. When symptomatic, patients usually report dyspnea, cough, or nonspecific chest discomfort. Spontaneous resolution of the disease is common, but progressive and disabling organ failure can occur in up to 10 percent of patients.",
"   </p>",
"   <p>",
"    Glucocorticoids are the most commonly used medication for the treatment of pulmonary sarcoidosis, although no medications have been approved by the Food and Drug Administration for the treatment of sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. However, some patients with sarcoidosis cannot tolerate or do not respond to glucocorticoids. Several alternative approaches have been proposed, such as the use of immunosuppressive, cytotoxic, and antimalarial drugs. In addition, irradiation has been used for neurosarcoidosis and organ transplantation has been performed successfully for end-stage hepatic, renal, cardiac, or pulmonary disease complicating sarcoidosis. Unfortunately, limited data exist regarding the indications and efficacy of these approaches in the management of pulmonary sarcoidosis.",
"   </p>",
"   <p>",
"    The treatment of pulmonary sarcoidosis with alternatives to glucocorticoids will be reviewed here. The diagnosis, treatment approach, and use of glucocorticoids for sarcoidosis affecting the lungs and other organs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/43/11961?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20616?source=see_link&amp;anchor=H11#H11\">",
"     \"Neurologic sarcoidosis\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/12/11463?source=see_link&amp;anchor=H11#H11\">",
"     \"Sarcoid arthropathy\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40438?source=see_link\">",
"     \"Renal disease in sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/14/17638?source=see_link&amp;anchor=H13#H13\">",
"     \"Gastrointestinal sarcoidosis\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/19/17722?source=see_link&amp;anchor=H22304146#H22304146\">",
"     \"Cardiac sarcoidosis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reasons to consider using agents other than glucocorticoids for the treatment of sarcoidosis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progression of the disease despite adequate glucocorticoid therapy. An adequate trial of glucocorticoid therapy is considered to be a minimum of 15 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      daily (or its equivalent) for at least three months.",
"     </li>",
"     <li>",
"      Intolerable glucocorticoid side effects (eg, difficult to control diabetes mellitus, excessive weight gain, myopathy, osteoporosis).",
"     </li>",
"     <li>",
"      Need for a glucocorticoid-sparing agent in a patient who requires long-term glucocorticoid therapy, has been unable to taper below 10 to 15",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      and has had at least one documented problem with glucocorticoid toxicity.",
"     </li>",
"     <li>",
"      Patient refusal to take glucocorticoids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior to intensifying therapy for pulmonary sarcoidosis, we investigate possible reasons for lack of clinical improvement, such as noncompliance with systemic glucocorticoids, comorbid disease, and end-stage fibrosis. Noncompliance with glucocorticoid therapy is common, due to the numerous side effects of glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/5\">",
"     5",
"    </a>",
"    ]. Sometimes patients will admit on questioning that they have been missing doses due to fear about the potential side effects. This is helpful information when assessing the likelihood of a response to another potentially toxic agent.",
"   </p>",
"   <p>",
"    We also assess patients for comorbid diseases that may contribute to their symptoms, pulmonary function impairment, or radiographic abnormalities (eg, infection, heart failure, thromboembolic disease, pulmonary hypertension) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Testing typically includes repeat pulmonary function tests and a high resolution computed tomography (HRCT) scan, and often an echocardiogram. This is also a good time to ask the patient again about a possible occupational exposure to beryllium or any exposure that could cause hypersensitivity pneumonitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16889?source=see_link&amp;anchor=H7#H7\">",
"     \"Pulmonary hypertension associated with interstitial lung disease\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/45/22234?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic beryllium disease (berylliosis)\", section on 'Exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    End-stage fibrosis is not responsive to immunosuppressive therapy, so it is important to determine whether a patient with apparently refractory disease has end-stage fibrosis or refractory but active inflammation. Chest imaging is not precise enough in most patients to exclude the presence of active disease in a severely scarred lung. On the other hand, pulmonary function test (PFT) abnormalities that have been stable for a few years are more likely due to fibrosis than active inflammation, although the stability of PFT abnormalities does not entirely exclude reversibility. If it is uncertain whether the patient has end-stage fibrosis without active disease, one or two second-line immunosuppressive agents are often tried before deciding that the patient has stable fibrosis and is not in need of ongoing therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MOST COMMONLY USED AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of immunosuppressive agents have been used to treat refractory pulmonary sarcoidosis. The evidence in support of individual second-line agents is largely observational [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The agents that appear to have the greatest likelihood of benefit with an acceptable side effect profile are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    , and antimalarial agents. All of the alternative agents for patients with refractory pulmonary sarcoidosis carry substantial risk for toxicity, particularly myelosuppression, hepatotoxicity, and opportunistic infection. The specific toxicities and ways to reduce their impact should be carefully reviewed with the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    (MTX), an antimetabolite with both immunosuppressive and antiinflammatory properties, is the most commonly used nonglucocorticoid immunosuppressive agent for sarcoidosis. It is also used for the management of other chronic inflammatory or autoimmune disorders, such as rheumatoid arthritis, psoriasis, and Crohn&rsquo;s disease. The mechanism of action of MTX and its use in these other diseases are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of psoriatic arthritis\", section on 'Methotrexate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7673?source=see_link&amp;anchor=H13#H13\">",
"     \"Immunomodulator therapy in Crohn's disease\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8636968\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small randomized trial, several small series, and case reports suggest that MTX is effective in patients with sarcoidosis affecting the lungs, skin, eyes, and central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/10-19\">",
"     10-19",
"    </a>",
"    ]. As an example, 24 patients with recent-onset pulmonary sarcoidosis were randomly assigned to low-dose MTX plus glucocorticoids or glucocorticoids alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/18\">",
"     18",
"    </a>",
"    ]. At 12 months, those in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    group had been able to taper",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    to a lower dose than those without MTX. However, when the study was analyzed including all the patients who had dropped out, the benefit was no longer statistically significant.",
"   </p>",
"   <p>",
"    Clinical experience suggests a response rate to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    of 40 to 60 percent among patients with pulmonary sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/5,17\">",
"     5,17",
"    </a>",
"    ]. A systematic review did not find convincing evidence of benefit, but this was due to insufficient published data, rather than demonstrated lack of benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265672417\">",
"    <span class=\"h3\">",
"     Pretreatment preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to initiating MTX, complete blood counts, albumin, aminotransferases, creatinine, and hepatitis B and C viral testing (ie, HBsAg, anti-HBc, anti-HCV) are obtained. Patients with evidence of underlying liver disease (eg, aminotransferase level above two times the upper limit of normal) or chronic infection with hepatitis B or C are not candidates for MTX therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/21\">",
"     21",
"    </a>",
"    ]. A creatinine clearance less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    is considered a contraindication for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in patients with rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=see_link&amp;anchor=H7#H7\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, ingestion of alcoholic beverages while using MTX is strongly discouraged, and patients who are unwilling to reduce their alcohol consumption to an occasional and minimal level are not treated with MTX.",
"   </p>",
"   <p>",
"    MTX is contraindicated in pregnancy due to teratogenic effects. Women of child-bearing age should use a reliable method of contraception while taking MTX. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H17#H17\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265672410\">",
"    <span class=\"h3\">",
"     Dosage and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;MTX can be administered either orally or intramuscularly. We typically begin with oral therapy at a dose of 7.5 mg weekly. The dose is gradually increased (eg, by increments of 2.5 mg every two weeks) until a dose of 10 to 15 mg per week is achieved. We switch to intramuscular MTX when patients have refractory nausea or have not achieved a beneficial effect after three to six months of oral therapy at 15 mg per week. A trial of MTX therapy should last at least six months to allow adequate assessment of effectiveness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/43/11961?source=see_link&amp;anchor=H348701692#H348701692\">",
"     \"Treatment of pulmonary sarcoidosis with glucocorticoids\", section on 'Assessing the response'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    at a dose of 1 mg per day is routinely given to patients on chronic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy to reduce the incidence of myelosuppression. A routine peripheral blood count is obtained every four to eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal frequency for assessing liver function tests during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy for sarcoidosis is unknown. Liver function tests are usually obtained every four weeks for the first three months of therapy, and afterwards every 8 to 12 weeks. Because hepatic toxicity may initially be clinically occult, some have advocated liver biopsy when the total dose exceeds one gram or after 18 to 24 months of therapy, even without signs of hepatic injury, or if 6 of 12 serum aminotransferase levels are abnormal in a single year. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=see_link&amp;anchor=H2#H2\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\", section on 'Hepatotoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8637177\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most serious side effects of immunosuppressive MTX therapy are hepatic fibrosis (in up to 10 percent of cases when the dose exceeds 5 g), leukopenia, and interstitial pneumonitis, resulting in pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/5\">",
"     5",
"    </a>",
"    ]. In a study of the long-term use of MTX for sarcoidosis, 50 patients completed two years of therapy; the major adverse effects requiring hospitalization were hepatic toxicity and leukopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=see_link&amp;anchor=H5#H5\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\", section on 'Guidelines in other rheumatic diseases'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=see_link&amp;anchor=H9#H9\">",
"     \"Methotrexate-induced lung injury\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of abnormal liver function in patients with sarcoidosis receiving MTX is broad and includes drug toxicity and hepatic sarcoidosis. Liver biopsy is frequently required to establish a definitive diagnosis. In a series of one hundred liver biopsies performed in 68 patients with sarcoidosis, 14 biopsies demonstrated significant changes related to MTX; however, evidence of sarcoidosis involving the liver was even more common, noted in 47 biopsies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/22\">",
"     22",
"    </a>",
"    ]. Toxic reactions to MTX eventually developed in 10 percent of patients treated for more than two years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40406?source=see_link&amp;anchor=H6#H6\">",
"     \"Hepatic granulomas\", section on 'Sarcoidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    -induced interstitial pneumonitis may be difficult to distinguish from progressive interstitial lung changes secondary to sarcoidosis. Characteristic features of MTX-induced lung injury include nonproductive cough, dyspnea, and fever beginning within days to weeks after initiation of MTX therapy. Peripheral blood (but not pulmonary) eosinophilia, when present, is more likely due to methotrexate than sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Typical radiographic findings of MTX-induced lung injury include diffuse or patchy ground glass opacities, centrilobular nodules, and increased reticular opacities; pleural effusion is seen in about 10 percent. Poorly formed granulomas may be seen on lung biopsy. Recovery usually occurs after withdrawal of the drug. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other toxicities include nausea, alopecia, and skin rash [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/5\">",
"     5",
"    </a>",
"    ]. MTX is known to be teratogenic and may transiently suppress gonadal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic MTX treatment has been associated with the development of lymphoproliferative disorders, some of which regress after discontinuation of MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. It is not known whether MTX had an etiologic role in the development of the lymphoproliferative disease, or whether the underlying inflammatory condition was the sole contributor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35496?source=see_link&amp;anchor=H21#H21\">",
"     \"Malignancy and rheumatic disorders\", section on 'Antirheumatic medications: Risk of malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    affects synthesis of RNA and DNA, thus inhibiting lymphocyte proliferation. Cellular immunity is suppressed to a greater degree than humoral immunity, but the exact mechanism by which azathioprine might affect sarcoidosis is not clear. Azathioprine is used as second line therapy for pulmonary sarcoidosis, generally as a supplement to glucocorticoids rather than as a single drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/1,16,28-33\">",
"     1,16,28-33",
"    </a>",
"    ]. Due to the greater clinical experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX), azathioprine is usually used in patients who have failed MTX due to side effects or lack of benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8637874\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have examined the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    for pulmonary sarcoidosis. An open-label series examined the effect of azathioprine (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) combined with glucocorticoids in 11 patients with chronic or relapsing pulmonary sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/32\">",
"     32",
"    </a>",
"    ]. All of the patients experienced improvement in symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary function tests. Therapy was continued for a mean of 20 months (range 8 to 26). Three patients, including the one who discontinued therapy after 8 months, sustained relapses at 8, 18, and 22 months. The remaining eight had stable remissions for at least 4 to 73 months after discontinuing therapy.",
"   </p>",
"   <p>",
"    In a separate series, 7 of 10 patients with pulmonary sarcoidosis exhibited clinical improvement with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    150 mg per day without concomitant glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/30\">",
"     30",
"    </a>",
"    ]. In contrast, a retrospective case review found a benefit in only 2 of 10 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265672451\">",
"    <span class=\"h3\">",
"     Pretreatment preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The toxicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is largely related to its metabolites and is strongly affected by the presence of genetic polymorphisms of the enzyme thiopurine-S-methyltransferase (TPMT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/35\">",
"     35",
"    </a>",
"    ]. TPMT activity can be predicted by genotyping or by measurement of serum TPMT enzyme activity levels. Low TPMT enzyme activity levels are associated with increased toxicity. Pretreatment screening of patients for genetic polymorphisms of TPMT or reduced TPMT enzyme activity is controversial as patients with normal genotypes can still develop myelosuppression and hepatic toxicity. However, many clinicians perform one test or another before initiating azathioprine therapy. It is not known whether a high level of TPMT activity would identify patients who need a higher dose of azathioprine to achieve a therapeutic effect. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44566?source=see_link&amp;anchor=H2#H2\">",
"     \"6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine\", section on 'TPMT enzyme determination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link&amp;anchor=H4#H4\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Pharmacogenetics and TPMT testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Baseline complete blood counts and serum albumin, aminotransferases, and creatinine are obtained in all patients.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    is a teratogen, so women of child-bearing age should use a reliable method of contraception during azathioprine therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H9#H9\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Azathioprine and 6-MP'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8637858\">",
"    <span class=\"h3\">",
"     Dosage and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is 50 mg per day, given as a single daily oral dose. To reduce the likelihood of gastrointestinal side effects, the dose is slowly increased by 25 mg every two to three weeks until the desired dose is reached. The typical maintenance dose is 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (up to a maximum of 200",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    unless the patient has renal insufficiency or an adverse effect necessitating a lower dose. We monitor the white blood cell count and reduce the azathioprine dose if the count falls to",
"    <span class=\"nowrap\">",
"     4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    A discernible response to therapy may not be evident until the patient has received three to six months of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A complete blood count (including hemoglobin, white blood cell count, and platelet count) should be monitored every week during dose escalation, and every 8 to 12 weeks after a stable dose is achieved. There is less consensus on the frequency of liver enzyme testing. A reasonable protocol is to check serum aminotransferases every 8 to 12 weeks during the first several months of AZA therapy and then less often during chronic therapy if prior testing has been normal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link&amp;anchor=H4#H4\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Pharmacogenetics and TPMT testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44566?source=see_link&amp;anchor=H9#H9\">",
"     \"6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8637851\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal complaints (eg, nausea, vomiting, and diarrhea), rash, fever, and malaise are the most common side effects. Dyspeptic symptoms can be reduced by taking the medication with meals. Hematologic side effects include depression of all cell lines, which may be difficult to distinguish from the bone marrow suppression associated with sarcoidosis. A small percentage of patients demonstrate an increase in liver function tests, but reports of severe hepatitis are rare. An increased risk of subsequent malignancy has been reported in renal transplant patients who are treated with both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8637583\">",
"    <span class=\"h2\">",
"     Leflunomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     Leflunomide",
"    </a>",
"    is an antimetabolite similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    but with less gastrointestinal toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98366759\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence in favor of using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    for pulmonary sarcoidosis is limited to case series and to indirect evidence of benefit in a few cases of extrapulmonary sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. In a retrospective case series, 32 patients received leflunomide with or without concomitant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    for pulmonary or ocular sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/36\">",
"     36",
"    </a>",
"    ]. Complete or partial response was seen in 12 of 17 patients who received leflunomide alone. Three patients discontinued leflunomide due to nausea, but no other significant side effects were reported. The combination of leflunomide with methotrexate resulted in a partial or complete response in 13 of 15 patients. In a case report, a patient with pulmonary, sinus, and cutaneous sarcoidosis that was refractory to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    responded to leflunomide 20 mg per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/38\">",
"     38",
"    </a>",
"    ]. He had been intolerant of MTX, but tolerated leflunomide without side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1807869\">",
"    <span class=\"h3\">",
"     Pretreatment preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to initiating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    therapy, complete blood counts, albumin, aminotransferases, creatinine, and hepatitis B and C viral testing are obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients with evidence of underlying liver disease (eg, aminotransferase level above two times the upper limit of normal) or chronic infection with hepatitis B or C are not candidates for leflunomide therapy.",
"   </p>",
"   <p>",
"    Alcohol avoidance is recommended while taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Both women and men",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    their female partners) of childbearing age should use a reliable method of contraception during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    therapy and for up to two years afterwards, unless they follow a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    clearance regimen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H19#H19\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Leflunomide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98366576\">",
"    <span class=\"h3\">",
"     Dosage and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typically initial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    dose is 20 mg per day, without a loading dose. We do not use a loading dose as a greater incidence of side effects was noted when a loading dose of 100 mg per day for three days was used in the treatment of rheumatoid arthritis. Alternatively, leflunomide can be initiated at 10 mg per day and increased to 20 mg, if the patient is tolerating the medication but has not achieved control of the disease manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=see_link&amp;anchor=H3#H3\">",
"     \"Leflunomide in the treatment of rheumatoid arthritis\", section on 'Dose and pharmacokinetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extrapolating from the experience with rheumatoid arthritis, it may take 6 to 12 weeks for any improvement in lung function to occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98366584\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    are nausea, diarrhea, abdominal pain, hepatotoxicity, rash, and peripheral neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. This risk of hepatotoxicity appears higher among patients with underlying liver disease (eg, alcohol abuse, viral hepatitis, autoimmune liver disease) who are taking another hepatotoxic agent. The frequency of adverse effects may be influenced by the patient&rsquo;s genotype at the locus for cytochrome P450, CYP1A2, or for dihydroorotate dehydrogenase, an enzyme inhibited by leflunomide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. However, testing for these genotypes is not clinically available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=see_link&amp;anchor=H5#H5\">",
"     \"Leflunomide in the treatment of rheumatoid arthritis\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American College of Rheumatology suggests that patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    undergo monitoring of serum albumin and aspartate and alanine aminotransferase levels every two to four weeks for the first three months, followed by monitoring every 8 to 12 weeks for the next three months, and then every 12 weeks thereafter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/21\">",
"     21",
"    </a>",
"    ]. Alcohol avoidance is recommended during leflunomide therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265672239\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have progressive pulmonary sarcoidosis that is refractory to one or two of these second-line immunosuppressive agents taken individually, a common practice is to combine two of the agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/43\">",
"     43",
"    </a>",
"    ]. As an example, in an open label study, 15 of 17 patients with sarcoidosis affecting various organs responded to a combination of methotrexate and leflunomide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/36\">",
"     36",
"    </a>",
"    ]. Alternatively, the tumor necrosis factor alpha (TNFa) antagonist,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , may be combined with one of these second-line agents, as described below. (See",
"    <a class=\"local\" href=\"#H26465141\">",
"     'Tumor necrosis factor antagonists'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10511427\">",
"    <span class=\"h2\">",
"     Antimalarial agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    are antimalarial drugs with immunomodulating properties. Clinical experience with chloroquine for pulmonary sarcoidosis is limited, and its relative efficacy versus other therapies has not been assessed. Due to the limited benefit and substantial toxicity, we avoid this medication except in circumstances where other options have failed or are contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10511800\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    has been used most often to treat cutaneous sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], but several reports have described its use in patients with pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/9,46-52\">",
"     9,46-52",
"    </a>",
"    ]. As an example, one trial treated 23 symptomatic patients with biopsy proven pulmonary sarcoidosis for six months with chloroquine, and then randomized patients to either maintenance therapy with chloroquine or observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/52\">",
"     52",
"    </a>",
"    ]. Small but statistically significant advantages in FEV1 and relapse rate were observed in the group maintained on chloroquine during a mean follow up of 20 months. In cutaneous sarcoidosis, chloroquine appears to have a higher response rate than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10511807\">",
"    <span class=\"h3\">",
"     Dosage and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose-6-phosphate dehydrogenase (G6PD) levels must be determined prior to initiating therapy; these agents cannot be given if the patient is G6PD deficient. For patients with a normal G6PD level, the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    is usually 250 mg to 750 mg given orally daily or every other day for six to nine months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/52\">",
"     52",
"    </a>",
"    ]. The switch to alternate day therapy may be made once the disease has stabilized, if continued therapy is necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39719?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10511814\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major adverse effects of the antimalarial agents are irreversible retinopathy and blindness. Thus, eye examination by an ophthalmologist is required at baseline and every 6 to 12 months during therapy to avoid drug-related toxic retinitis and corneal lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/5\">",
"     5",
"    </a>",
"    ]. Alternate day treatment minimizes the risk of ocular toxicity.",
"    <br/>",
"    <br/>",
"    Nausea is a frequent dose-limiting problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26465141\">",
"    <span class=\"h1\">",
"     TUMOR NECROSIS FACTOR ANTAGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cytokine tumor necrosis factor alpha (TNFa) is thought to accelerate the inflammatory process in sarcoidosis via its role in maintenance of granuloma formation. Thus, using agents that block the effect of TNFa may be beneficial in treating sarcoidosis. Due to the potential toxicity of these agents, we reserve them for patients who have persistent disease despite treatment with glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    &ge;15",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    AND at least one second-line immunosuppressive agent (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/4,54,55\">",
"     4,54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26465386\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the efficacy of TNFa antagonist agents in the treatment of sarcoidosis have yielded mixed results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      (ie, Remicade) is a chimeric, humanized monoclonal antibody that neutralizes TNFa. It has been studied in patients with pulmonary and extrapulmonary sarcoidosis refractory to glucocorticoid therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/56-62\">",
"       56-62",
"      </a>",
"      ]. In a double-blind trial, 138 patients with chronic pulmonary sarcoidosis were randomly assigned to receive infusions of placebo, low-dose infliximab (3",
"      <span class=\"nowrap\">",
"       mg/kg),",
"      </span>",
"      or higher-dose infliximab (5",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      at baseline and weeks 2, 6, 12, 18, and 24 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/60\">",
"       60",
"      </a>",
"      ]. At evaluations performed at 24 and 52 weeks, low-dose infliximab increased the percent of predicted forced vital capacity (FVC) compared to baseline, whereas placebo did not. The proportion of patients that reported adverse events was similar among the treatment groups; the most common adverse events were upper respiratory infection, cough, dyspnea, and bronchitis.",
"      <br/>",
"      <br/>",
"      The infliximab trial described above has been criticized for its small and clinically insignificant effect size, although it did identify subgroups that may derive greater benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/60,63\">",
"       60,63",
"      </a>",
"      ]. As an example, 92 patients with extrapulmonary sarcoidosis that was refractory to chronic glucocorticoids were randomly assigned to take infliximab or placebo for 24 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/64\">",
"       64",
"      </a>",
"      ]. A modest improvement was noted in the infliximab group, although the improvement was not maintained during the 24 month follow-up period. Long-term infliximab treatment has not been well studied. Patients with predominantly extrapulmonary sarcoidosis appear to receive the most benefit from long-term treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/62\">",
"       62",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Preliminary evidence suggests that a subset of patients with sarcoidosis who have peripheral blood CD4+ T cell lymphopenia and resistance to conventional immunosuppressants may be more likely to respond to infliximab [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/65\">",
"       65",
"      </a>",
"      ]. Among five consecutive patients with this phenotype, the CD4+ lymphopenia corrected with infliximab and all reported improvement in at least one clinical disease manifestation of sarcoidosis. Additional studies regarding the cause of the CD4+ lymphopenia in these patients and the use of CD4+ lymphopenia as a biomarker for response to infliximab are needed.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      (ie, Humira) is a fully human anti-TNFa antibody. A few case reports and small case series have described improvement in extrapulmonary sarcoidosis with adalimumab [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/66-70\">",
"       66-70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      (ie, Enbrel) is a soluble TNFa receptor fusion protein that binds TNFa and has a longer half-life than the native soluble receptor. It was assessed in a preliminary clinical trial of patients with progressive stage II or III sarcoidosis. The trial was stopped after the enrollment of 17 patients, when interval assessment noted treatment failure in 11 participants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/71\">",
"       71",
"      </a>",
"      ]. Treatment failure was defined as progressive clinical deterioration, the need for other immunosuppressive medications, or the development of intolerable side effects. In a separate trial, etanercept was not shown to improve chronic ocular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/72\">",
"       72",
"      </a>",
"      ]. On the basis of these results, larger trials of this agent for progressive pulmonary sarcoidosis do not appear indicated.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"       Golimumab",
"      </a>",
"      is a humanized anti-TNFa antibody that has been found effective for rheumatoid arthritis. A clinical trial of golimumab for sarcoidosis is in progress.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265670874\">",
"    <span class=\"h2\">",
"     Pretreatment preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy with TNFa antagonists has been associated with reactivation of a variety of latent infections including tuberculosis and hepatitis B.",
"   </p>",
"   <p>",
"    Prior to initiating therapy with a TNFa antagonist, patients are asked about risk factors for tuberculosis infection and undergo a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    (PPD) or a peripheral blood interferon release assay. For patients who have been previously vaccinated with BCG, the interferon release assay can help to differentiate between tuberculosis infection and BCG vaccination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=see_link&amp;anchor=H15#H15\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\", section on 'Screening and prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37160?source=see_link\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Flares of hepatitis B have been documented with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    therapy, but small studies of patients with hepatitis C have not shown activation of hepatitis C or an increase in viral load. We ask patients about risk factors for hepatitis viral infection and obtain serologic testing for hepatitis B and C. Serologic testing should include assessment of HBsAg, anti-HBc, and anti-HCV. If the HBsAg test is positive, further testing should include HBeAg, anti-HBe, and an HBV DNA level. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=see_link&amp;anchor=H25#H25\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\", section on 'Hepatotoxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link&amp;anchor=H3#H3\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\", section on 'Settings in which flares have been described'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=see_link&amp;anchor=H9#H9\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\", section on 'Viral infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265670867\">",
"    <span class=\"h2\">",
"     Dosage and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    is administered by intravenous infusion 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at weeks 0, 2, 6, and 12 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/59-61,65\">",
"     59-61,65",
"    </a>",
"    ]. The optimal frequency for subsequent dosing is not known. Among patients with rheumatoid arthritis and Crohn&rsquo;s disease, scheduled maintenance therapy (eg, every six to eight weeks) appears more effective than no maintenance therapy. The optimal duration of a therapeutic trial of infliximab in pulmonary sarcoidosis is unknown, but a six month trial was better than a three month trial in a group of 244 patients with rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/10/10410?source=see_link&amp;anchor=H4#H4\">",
"     \"Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis\", section on 'Infliximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    is administered by subcutaneous injection. The optimal dose in pulmonary sarcoidosis is not known, but a dose of 40 mg every week or every other week has been used in case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. In other inflammatory conditions, the usual dose is 40 mg every other week; sometimes an initial dose of 80 to 160 mg (given as 4 injections over 24 hours) is used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29559?source=see_link&amp;anchor=H8#H8\">",
"     \"Adalimumab for treatment of Crohn's disease in adults\", section on 'Dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26465635\">",
"    <span class=\"h2\">",
"     Combination with other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    appears to inhibit antibody formation to infliximab and to improve disease control among patients with rheumatoid arthritis or Crohn&rsquo;s disease. However, the risks of serious infection and malignancy (lymphoma) in these diseases appear greater with combination therapy, than with infliximab alone. Data for sarcoidosis are insufficient to make a clear recommendation between these choices. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/4/44105?source=see_link&amp;anchor=H12#H12\">",
"     \"Infliximab in Crohn's disease\", section on 'Use of immunosuppressive agents in combination with infliximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/10/10410?source=see_link&amp;anchor=H4#H4\">",
"     \"Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis\", section on 'Infliximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We typically initiate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    alone or in combination with a low-dose of glucocorticoid, rather than adding an alternate second-line agent to prevent antibody formation. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26465394\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major adverse effects associated with the TNFa antagonists are increased susceptibility to infection, particularly mycobacterial and invasive fungal infections, and infusion-reactions. Additional side effects reported in separate studies (in one patient each) include alopecia, oral candidiasis, cellulitis, pneumonia, visual field defect, fatal pulmonary embolism, and development of a hypercoagulable state associated with circulating anticardiolipin antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/56-59,61\">",
"     56-59,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The development of noncaseating granulomas consistent with sarcoidosis has been reported during anti-TNFa therapy for other diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/74-77\">",
"     74-77",
"    </a>",
"    ] Granulomas have occurred in the skin, lungs, and lymph nodes. The sarcoid-like disease manifestations have typically resolved with cessation of anti-TNFa therapy, although some patients have also received glucocorticoid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8637575\">",
"    <span class=\"h1\">",
"     POTENTIAL TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several medications have been proposed for use in sarcoidosis based on their mechanism of action, but are not commonly used for pulmonary sarcoidosis due lack of adequate data to support their use or their side effect profile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8637469\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    is used rarely as a glucocorticoid-sparing agent in the treatment of sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Due to its toxicity profile, it is reserved for use as a \"third-line\" drug in patients whose condition is deteriorating despite therapy with glucocorticoids and one of the more commonly used immunosuppressive agents. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Most commonly used agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanism of action &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      is an alkylating agent of the nitrogen mustard group. It is an inactive drug that is metabolized by the cytochrome P-450 system into active metabolites. These metabolites decrease lymphocyte numbers and function and may also have anti-inflammatory effects. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"       \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dosage and administration &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      is generally given orally as a single daily dose. We usually begin at a dose of 25 to 50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and increase gradually, by 25 mg increments, aiming to reduce and maintain the white blood cell (WBC) count to between 4000 and",
"      <span class=\"nowrap\">",
"       7000/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"      The WBC count is measured biweekly for the first 6 to 12 weeks and then at least monthly thereafter. We do not exceed a dose of 150",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      even if the leukocyte count remains about",
"      <span class=\"nowrap\">",
"       7000/m",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      as it is our clinical impression that this dose is associated with a lower rate of side effects without loss of clinical efficacy. There is little experience in sarcoidosis with the intravenous administration of intermittent (\"pulse\") therapy with cyclophosphamide. It has been used occasionally in patients with refractory or progressive disease. The usual dose is 500 to 1000 mg given intravenously over 30 to 60 minutes once every two or four weeks; the exact dose is calculated based on the patient&rsquo;s age, creatinine clearance, and peripheral leukocyte counts during treatment. Intravenous administration is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=see_link\">",
"       \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We do not expect to achieve a favorable response to cyclophosphamide for at least three to six months after initiating therapy, either with or without accompanying low doses of glucocorticoids.",
"     </li>",
"     <li>",
"      Adverse effects &ndash; Reductions in all hematologic cell lines can be seen, and these require an adjustment in dosage. As discussed above, we adjust the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      dose to maintain the WBC count between 4000 and",
"      <span class=\"nowrap\">",
"       7000/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"      Other toxicities include increased risk of infection, hemorrhagic cystitis, stomatitis, nausea, diarrhea, hepatotoxicity (rarely), and carcinoma of the bladder. Strategies to reduce the risk of hemorrhagic cystitis include advising the patient to drink eight or more glasses (eight ounces each) of water daily to create a forced diuresis and monthly monitoring of the urine for red blood cells or other abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"       \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Infertility may occur in both men and women. Cyclophosphamide may be teratogenic, so women of childbearing age should use a reliable method of contraception. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H15#H15\">",
"       \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Cyclophosphamide'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265672173\">",
"    <span class=\"h2\">",
"     Endothelin receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that the antifibrotic effect of the endothelin receptor antagonists might be beneficial in interstitial lung diseases with a fibrotic component. A trial to assess the efficacy of the endothelin receptor antagonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    in patients with progressive pulmonary sarcoidosis with and without pulmonary hypertension was terminated due to difficulties with recruitment. A separate study of bosentan for sarcoidosis associated pulmonary hypertension is ongoing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16889?source=see_link&amp;anchor=H11#H11\">",
"     \"Pulmonary hypertension associated with interstitial lung disease\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265670931\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil, an inhibitor of lymphocyte proliferation and activity, has been used to treat a variety of interstitial lung diseases associated with collagen vascular disease. Its effect in pulmonary sarcoidosis is not known, but benefit has been reported in case series of patients with cutaneous, central nervous system, and renal sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/80-83\">",
"     80-83",
"    </a>",
"    ]. In a case report, cutaneous and bone marrow sarcoidosis that were refractory to glucocorticoids and mycophenolate responded to a combination of mycophenolate and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8313?source=see_link&amp;anchor=H7#H7\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Treatment\", section on 'Mycophenolate mofetil'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20616?source=see_link&amp;anchor=H13#H13\">",
"     \"Neurologic sarcoidosis\", section on 'Other immunomodulatory therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neutropenia is less of a problem with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    than with other immunosuppressive agents, but may occur. Nausea and diarrhea may be dose limiting.",
"   </p>",
"   <p>",
"    Further study is needed to determine whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    has a beneficial role in the treatment of pulmonary sarcoidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9819076\">",
"    <span class=\"h2\">",
"     Pentoxifylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"     Pentoxifylline",
"    </a>",
"    is a xanthine that has hemorheologic activity (improves blood flow), leading to its use in the treatment of vascular insufficiency. In addition, pentoxifylline inhibits the synthesis of tumor necrosis factor-alpha by alveolar macrophages from patients with sarcoidosis, potentially inhibiting the formation and maintenance of granulomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. As a result, it has been postulated that pentoxifylline might have a beneficial clinical effect in patients with sarcoidosis; however, its use for this indication remains experimental.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Efficacy &ndash; In a preliminary study, 23 untreated patients with active sarcoidosis were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      ; improvement was noted in 11 patients, while 7 patients remained stable and none deteriorated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/87\">",
"       87",
"      </a>",
"      ]. Three patients discontinued therapy because of gastrointestinal side effects. Three patients whose sarcoidosis was refractory to glucocorticoids had improvement following addition of pentoxifylline to the glucocorticoid regimen. In a separate trial, 27 patients with pulmonary sarcoidosis were randomly assigned to pentoxifylline with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or prednisone alone; no benefit was found in pulmonary function parameters or dyspnea, although a post hoc analysis found a diminution in flares of sarcoidosis and in the prednisone usage with pentoxifylline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Side effects &ndash; The primary side effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      are gastrointestinal, and are similar to those of other xanthine agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/87,88\">",
"       87,88",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32410?source=see_link&amp;anchor=H17#H17\">",
"       \"Medical management of lower extremity chronic venous disease\", section on 'Pentoxifylline'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9818587\">",
"    <span class=\"h1\">",
"     AGENTS THAT ARE AVOIDED",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of agents have substantial toxicity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    insufficient evidence of benefit for pulmonary sarcoidosis and are consequently avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9818649\">",
"    <span class=\"h2\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    has multiple effects, including the arrest of cell division, inhibition of granulocyte migration, and inhibition of the release of several proteins from cells. It may also interfere with the secretion of collagen from fibroblasts and may increase collagen degradation by enhancing the action of collagenase. Colchicine may be useful for sarcoid arthritis (based on case series), but is not used for pulmonary sarcoidosis. &nbsp;",
"   </p>",
"   <p>",
"    Side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    include nausea, vomiting, abdominal pain, and diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9818656\">",
"    <span class=\"h2\">",
"     Chlorambucil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     Chlorambucil",
"    </a>",
"    is rarely used for the treatment of refractory pulmonary sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/28,89-92\">",
"     28,89-92",
"    </a>",
"    ]. Clinical experience is limited, and the relative efficacy of chlorambucil versus other therapies has not been assessed. Due to the limited benefit and substantial toxicity, we avoid this medication except in circumstances where other options have failed or are contraindicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanism of action &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       Chlorambucil",
"      </a>",
"      is an alkylating agent related to nitrogen mustard. At high doses, it suppresses all myeloid elements, and the therapeutic strategy in sarcoidosis is to selectively suppress immune function, via lymphocyte reduction, before the suppression of other bone marrow cells.",
"     </li>",
"     <li>",
"      Efficacy &ndash; The evidence in favor of using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      for sarcoidosis is limited. In one report, 10 patients with progressive disease were treated with chlorambucil alone or in combination with glucocorticoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/89\">",
"       89",
"      </a>",
"      ]. Eight had some degree of improvement that may have been attributable to chlorambucil. The responsive patients showed beneficial effects within three months of starting chlorambucil therapy.",
"     </li>",
"     <li>",
"      Adverse effects &ndash; Bone marrow function usually recovers rapidly when the drug is discontinued, but irreversible marrow failure has also been reported. An alarming rate of oncogenesis (leukemia and other tumors) limits its potential use in nonneoplastic diseases. Other side effects include nausea, vomiting, hepatotoxicity, dermatitis, and infertility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9818847\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    , a fungus-derived cyclic peptide, is primarily used for the prevention of allograft rejection. In addition, it may be effective in T-cell mediated disorders such as uveitis, psoriasis, rheumatoid arthritis, and primary biliary cirrhosis. The use of cyclosporine in the treatment of pulmonary sarcoidosis remains experimental, due to limited clinical experience and known toxicities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/93-97\">",
"     93-97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanism of action &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      exerts an inhibitory effect on T cells by interfering with the synthesis of lymphokines. It is known to suppress an antibody response to T cell-dependent antigens, delayed type hypersensitivity, and allograft rejection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"       \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Because cyclosporine has specific inhibitory effects on T-lymphocyte activation, it has been proposed that this agent may suppress activated T-cells in the lungs of patients with sarcoidosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/95\">",
"       95",
"      </a>",
"      ]. This effect was confirmed in vitro: the addition of cyclosporine to T cells recovered from the lungs of patients with active sarcoid suppressed the spontaneous release of interleukin-2 (IL-2) and monocyte chemotactic factor by these cells and inhibited their spontaneous replication.",
"     </li>",
"     <li>",
"      Efficacy &ndash; The limited clinical experience with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      for pulmonary sarcoidosis has not demonstrated significant improvement in control of the disease. As an example, one study randomly assigned 37 patients with biopsy-proven sarcoidosis and deteriorating respiratory function to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      with or without concomitant, open-label cyclosporine, titrated to trough levels of 100 to 200",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/97\">",
"       97",
"      </a>",
"      ]. Combined outcome measures did not differ significantly between the two treatment groups at 3, 9, or 18 months, and side effects such as hypertrichosis, paresthesias, and hypercholesterolemia were significantly more frequent among cyclosporine-treated patients. It is possible that the small trials in which its use has been studied have had insufficient power to detect beneficial effects of cyclosporine treatment or that only selected subgroups of patients will derive a benefit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Adverse effects &ndash; The major adverse reactions are renal dysfunction, tremor, hirsutism, hypertension, and gum hyperplasia. There is apparently no myelotoxicity associated with the therapeutic use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      . Many drugs interfere with the metabolism of cyclosporine. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"       \"Cyclosporine and tacrolimus nephrotoxicity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link&amp;anchor=H17#H17\">",
"       \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Side effects'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nonsteroidal anti-inflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     Ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    , or salicylates may help reduce acute inflammatory or constitutional symptoms of sarcoidosis (eg, arthritis and fever), but are not recommended for the treatment of pulmonary sarcoidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376141074\">",
"    <span class=\"h2\">",
"     Tetracyclines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    family (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ) have been used to treat cutaneous sarcoidosis with variable effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/98\">",
"     98",
"    </a>",
"    ]. There is insufficient evidence of benefit to use these agents for the treatment of pulmonary sarcoidosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/20/19786?source=see_link\">",
"     \"Cutaneous manifestations of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376141081\">",
"    <span class=\"h2\">",
"     Thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    has antitumor necrosis factor (TNFa) activity and has been used to treat cutaneous sarcoidosis in a few patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. However, it does not appear to be of benefit in pulmonary sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/101\">",
"     101",
"    </a>",
"    ]. In an open label study, 10 patients with pulmonary sarcoidosis dependent on glucocorticoids received thalidomide 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 24 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/101\">",
"     101",
"    </a>",
"    ]. No significant improvement in dyspnea, pulmonary function, or quality of life occurred. A dose reduction was necessary in 9 of 10 patients due to side effects such as excess somnolence, constipation, and peripheral neuropathy. It is unlikely that patients would be able to tolerate the high doses of thalidomide that would likely be needed to treat pulmonary sarcoidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98367236\">",
"    <span class=\"h1\">",
"     OPPORTUNISTIC INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opportunistic infectious complications (eg, cryptococcosis) are rare in patients with sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/6,102\">",
"     6,102",
"    </a>",
"    ]. However, since opportunistic infections are a side effect of immunosuppressive therapies, such as the combination of glucocorticoids at a dose of 20 mg daily and another immunosuppressive agent (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    , tumor necrosis factor antagonists), it is important that clinicians monitor patients for this possibility. The types of infection associated with these therapies and the indications for preventive therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28249?source=see_link&amp;anchor=H22#H22\">",
"     \"Glucocorticoid effects on the immune system\", section on 'Infection risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ASSESSING RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to therapy with any of the agents described above is evaluated in the same manner as that described for glucocorticoid therapy of pulmonary sarcoidosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/43/11961?source=see_link&amp;anchor=H348701692#H348701692\">",
"     \"Treatment of pulmonary sarcoidosis with glucocorticoids\", section on 'Assessing the response'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, a favorable response to therapy is defined by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A decrease in symptoms, especially dyspnea, cough, hemoptysis, chest pain, or fatigue.",
"     </li>",
"     <li>",
"      A reduction or clearing of radiographic abnormalities.",
"     </li>",
"     <li>",
"      Physiologic improvement, such as a 10 to 15 percent or greater increase in forced vital capacity (FVC) or total lung capacity (TLC), a 20 percent or greater increase in diffusing capacity (DLCO).",
"     </li>",
"     <li>",
"      An improvement in gas exchange (a 4 mmHg or greater increase in the arterial partial pressure of oxygen (PaO",
"      <sub>",
"       2",
"      </sub>",
"      ) or a decline of 4 mmHg or more in the alveolar-arterial oxygen&nbsp;gradient at rest or during exercise).",
"     </li>",
"     <li>",
"      For patients with previously progressive disease, an absence of further decline in lung function or other parameters of disease activity for three to six months should also be considered a positive response to treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The parameters of response are sometimes conflicting and clinical judgement is needed to determine whether changes reflect true worsening or true improvement. Generally, greater weight is attributed to changes in symptoms than to changes in other parameters.",
"   </p>",
"   <p>",
"    In addition to assessing the response to therapy, patients are monitored for new, extrapulmonary manifestations of sarcoidosis on a regular basis. An approach to monitoring is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=see_link&amp;anchor=H41#H41\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LUNG TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with advanced pulmonary fibrosis due to pulmonary sarcoidosis and associated pulmonary hypertension, lung transplantation may offer the only hope for long-term survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/7,103,104\">",
"     7,103,104",
"    </a>",
"    ]. Patients considered for lung transplantation usually have stage IV radiographic disease (ie, advanced fibrotic changes, honeycombing, hilar retraction, and cystic change) and are New York Heart Association III or IV. Survival rates following lung transplantation for pulmonary sarcoidosis are comparable to those for other indications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/105-107\">",
"     105-107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3480?source=see_link\">",
"     \"Lung transplantation: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data are limited regarding the optimal timing of lung transplantation for sarcoidosis. Parameters that would favor a lung transplant evaluation include a forced vital capacity (FVC) less than 1.5 L (or less than 50 percent of predicted) and the development of oxygen dependence or pulmonary hypertension due to sarcoidosis, as these features are associated with increased one year mortality in the absence of transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When deciding between a single or double lung transplantation, the presence of a mycetoma or significant bronchiectasis may necessitate a double lung procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/105\">",
"     105",
"    </a>",
"    ]. In addition, patients with mycetomas may require specific, individualized antifungal therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. The extent of extrapulmonary sarcoidosis must be carefully assessed prior to surgery. In particular, cardiac involvement may indicate a greater risk from lung transplantation alone or the need for a simultaneous heart-lung transplantation. Heart-lung transplantation increases the risk for short-term posttransplant mortality, although long-term outcomes are comparable to double lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/105,112\">",
"     105,112",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=see_link&amp;anchor=H12#H12\">",
"     \"Lung transplantation: General guidelines for recipient selection\", section on 'Chronic infection or colonization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/19/17722?source=see_link&amp;anchor=H22304918#H22304918\">",
"     \"Cardiac sarcoidosis\", section on 'Surgery and transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following lung transplantation, asymptomatic foci of noncaseating granulomas, suggestive of recurrent disease, have been identified in the allografts of sarcoidosis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/113-117\">",
"     113-117",
"    </a>",
"    ]. However, clinically significant organ dysfunction due to recurrent sarcoidosis is rare, and evidence of recurrence usually disappears within three months, without associated clinical sequelae during the follow-up period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/103,104,107,115\">",
"     103,104,107,115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of acute rejection and bronchiolitis obliterans syndrome appear similar after transplantation among patients with sarcoidosis, idiopathic pulmonary fibrosis, and chronic obstructive pulmonary disease, despite observations to the contrary in the older literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/11/38074/abstract/107,114,115,117,118\">",
"     107,114,115,117,118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265672161\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information about clinical trials of therapies for pulmonary sarcoidosis can be found at",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/results?term=pulmonary+sarcoidosis\">",
"     file://clinicaltrials.gov/ct2/results?term=pulmonary+sarcoidosis",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PATIENT INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/14/20705?source=see_link\">",
"       \"Patient information: Sarcoidosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/35/5683?source=see_link\">",
"       \"Patient information: Sarcoidosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of patients with pulmonary sarcoidosis either do not require treatment at all or their disease responds well to systemic glucocorticoid therapy. However, progressive and disabling organ failure can occur in up to 10 percent of patients. For these patients, intensification of therapy with alternatives to glucocorticoids typically involves immunosuppressive agents. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to intensifying therapy for pulmonary sarcoidosis, we investigate possible reasons for lack of clinical improvement during therapy with systemic glucocorticoids, such as noncompliance, comorbid disease, and end-stage fibrosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.) All of the alternative agents for patients with refractory pulmonary sarcoidosis carry substantial risk for toxicity, particularly myelosuppression, hepatotoxicity, and opportunistic infection. Prior to initiating therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , baseline complete blood counts and serum aminotransferases, albumin, and creatinine are obtained. Assessment of hepatitis B or C infection is performed prior to methotrexate or leflunomide therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Most commonly used agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for alternative agents include lack of response to glucocorticoids, intolerable side effects of glucocorticoids, or inability to taper glucocorticoids below 10 to 15",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in a patient with at least one documented adverse effect from glucocorticoid therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/43/11961?source=see_link\">",
"       \"Treatment of pulmonary sarcoidosis with glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with pulmonary sarcoidosis refractory to systemic glucocorticoids, we suggest addition of another immunosuppressive agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ); choices include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , or an antimalarial agent. Methotrexate is usually the first choice due to a greater clinical experience in managing pulmonary sarcoidosis with this agent. If methotrexate is ineffective or not tolerated, we usually substitute azathioprine or leflunomide for the methotrexate. In most instances, we continue low-dose glucocorticoids (0.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, usually less than 20 mg per day). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Most commonly used agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with active pulmonary sarcoidosis who need to discontinue glucocorticoids due to adverse effects, we suggest substitution of a second-line immunosuppressive agent (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , antimalarial agents) for the glucocorticoid (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Most commonly used agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who do not respond to a trial of one or two of the second-line immunosuppressive agents given alone or in combination with glucocorticoids, the next step is either to combine two of the second-line immunosuppressive agents or to add the tumor necrosis factor-alpha (TNFa) antagonist",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      . The choice is usually guided by the individual patient&rsquo;s history of medication-related adverse effects, clinician experience with the agents, and patient preference. (See",
"      <a class=\"local\" href=\"#H265672239\">",
"       'Combination therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26465141\">",
"       'Tumor necrosis factor antagonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to initiation of therapy with a TNFa antagonist, patients are asked about risk factors for tuberculosis and are screened with a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      or peripheral blood interferon release assay. Patients are also asked about risk factors for hepatitis B and C and screened for these infections with testing for hepatitis B antigen (HBsAg), anti-hepatitis B core antibody (anti-HBc), and antihepatitis C antibody (anti-HCV). (See",
"      <a class=\"local\" href=\"#H26465141\">",
"       'Tumor necrosis factor antagonists'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37160?source=see_link\">",
"       \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Several medications proposed for pulmonary sarcoidosis are still considered experimental (eg, endothelin receptor antagonists,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      ) or are used infrequently due to their side effect profile (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8637575\">",
"       'Potential treatments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several medications proposed for use in pulmonary sarcoidosis are now avoided due to the lack of adequate supportive data or an adverse effect profile; these agents include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , nonsteroidal anti-inflammatory agents, tetracyclines, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H9818587\">",
"       'Agents that are avoided'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/1\">",
"      Baughman RP. Pulmonary sarcoidosis. Clin Chest Med 2004; 25:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/2\">",
"      Sharma OP. Pulmonary sarcoidosis and corticosteroids. Am Rev Respir Dis 1993; 147:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/3\">",
"      du Bois RM. Corticosteroids in sarcoidosis: friend or foe? Eur Respir J 1994; 7:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/4\">",
"      Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/5\">",
"      Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med 2008; 29:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/6\">",
"      Baughman RP, Lower EE. Fungal infections as a complication of therapy for sarcoidosis. QJM 2005; 98:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/7\">",
"      Shlobin OA, Nathan SD. Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. Eur Respir J 2012; 39:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/8\">",
"      Paramothayan S, Lasserson TJ, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev 2006; :CD003536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/9\">",
"      Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med 2010; 104:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/10\">",
"      Lacher MJ. Spontaneous remission or response to methotrexate in sarcoidosis. Ann Intern Med 1968; 69:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/11\">",
"      Fenton DA, Shaw M, Black MM. Invasive nasal sarcoidosis treated with methotrexate. Clin Exp Dermatol 1985; 10:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/12\">",
"      Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 1990; 299:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/13\">",
"      Suda T, Sato A, Toyoshima M, et al. Weekly low-dose methotrexate therapy for sarcoidosis. Intern Med 1994; 33:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/14\">",
"      Henderson CA, Ilchyshyn A, Curry AR. Laryngeal and cutaneous sarcoidosis treated with methotrexate. J R Soc Med 1994; 87:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/15\">",
"      Kaye O, Palazzo E, Grossin M, et al. Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol 1995; 34:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/16\">",
"      Agbogu BN, Stern BJ, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 1995; 52:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/17\">",
"      Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/18\">",
"      Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/19\">",
"      Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis 1990; 142:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/20\">",
"      Paramothayan S, Lasserson T. Treatments for pulmonary sarcoidosis. Respir Med 2008; 102:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/21\">",
"      Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/22\">",
"      Baughman RP, Koehler A, Bejarano PA, et al. Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch Intern Med 2003; 163:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/23\">",
"      Schnabel A, Richter C, Bauerfeind S, Gross WL. Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax 1997; 52:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/24\">",
"      Inokuma S, Kono H, Kohno Y, et al. Methotrexate-induced lung injury in patients with rheumatoid arthritis occurs with peripheral blood lymphocyte count decrease. Ann Rheum Dis 2006; 65:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/25\">",
"      Chikura B, Sathi N, Lane S, Dawson JK. Variation of immunological response in methotrexate-induced pneumonitis. Rheumatology (Oxford) 2008; 47:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/26\">",
"      Niitsu N, Okamoto M, Nakamine H, Hirano M. Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. Cancer Sci 2010; 101:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/27\">",
"      Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 2007; 34:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/28\">",
"      Gelwan MJ, Kellen RI, Burde RM, Kupersmith MJ. Sarcoidosis of the anterior visual pathway: successes and failures. J Neurol Neurosurg Psychiatry 1988; 51:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/29\">",
"      Elkin R, Willcox PA. Neurosarcoidosis. A report of 5 cases. S Afr Med J 1985; 67:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/30\">",
"      Pacheco Y, Marechal C, Marechal F, et al. Azathioprine treatment of chronic pulmonary sarcoidosis. Sarcoidosis 1985; 2:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/31\">",
"      O'Reilly BJ, Burrows EH. VIIIth cranial nerve involvement in sarcoidosis. J Laryngol Otol 1995; 109:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/32\">",
"      M&uuml;ller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/33\">",
"      Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 Suppl 5:v1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/34\">",
"      Lewis SJ, Ainslie GM, Bateman ED. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/35\">",
"      Bakker JA, Drent M, Bierau J. Relevance of pharmacogenetic aspects of mercaptopurine metabolism in the treatment of interstitial lung disease. Curr Opin Pulm Med 2007; 13:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/36\">",
"      Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/37\">",
"      Modrykamien A, Arrossi A, Reddy A. A 50-year-old man with stage 2 sarcoidosis with pleural involvement. J Hosp Med 2009; 4:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/38\">",
"      Majithia V, Sanders S, Harisdangkul V, Wilson JG. Successful treatment of sarcoidosis with leflunomide. Rheumatology (Oxford) 2003; 42:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/39\">",
"      Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/40\">",
"      Savage RL, Highton J, Boyd IW, Chapman P. Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Intern Med J 2006; 36:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/41\">",
"      Bohanec Grabar P, Rozman B, Tomsic M, et al. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008; 64:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/42\">",
"      Grabar PB, Rozman B, Logar D, et al. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/43\">",
"      Baughman RP, Ohmichi M, Lower EE. Combination therapy for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/44\">",
"      Johns CJ, Zachary JB, MacGregor MI, et al. The longitudinal study of chronic sarcoidosis. Trans Am Clin Climatol Assoc 1983; 94:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/45\">",
"      Zic JA, Horowitz DH, Arzubiaga C, King LE Jr. Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature. Arch Dermatol 1991; 127:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/46\">",
"      Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand Suppl 1964; 425:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/47\">",
"      Chloroquine in the treatment of sarcoidosis. A report from the Research Committee of the British Tuberculosis Association. Tubercle 1967; 48:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/48\">",
"      Krasnitz A. Chloroquine therapy in pulmonary sarcoidosis. N Y State J Med 1967; 67:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/49\">",
"      Brodthagen H. Chloroquine in pulmonary sarcoidosis. Lancet 1968; 1:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/50\">",
"      Chloroquine in pulmonary sarcoidosis. Lancet 1968; 1:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/51\">",
"      James DG, Barter S, Jash D, et al. Sarcoidosis of the upper respiratory tract (SURT). J Laryngol Otol 1982; 96:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/52\">",
"      Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999; 160:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/53\">",
"      Baughman RP, Lower EE. Evidence-based therapy for cutaneous sarcoidosis. Clin Dermatol 2007; 25:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/54\">",
"      Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/55\">",
"      Bargagli E, Olivieri C, Rottoli P. Cytokine modulators in the treatment of sarcoidosis. Rheumatol Int 2011; 31:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/56\">",
"      Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004; 63:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/57\">",
"      Ulbricht KU, Stoll M, Bierwirth J, et al. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum 2003; 48:3542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/58\">",
"      Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 2001; 135:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/59\">",
"      Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/60\">",
"      Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/61\">",
"      Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/62\">",
"      Hostettler KE, Studler U, Tamm M, Brutsche MH. Long-term treatment with infliximab in patients with sarcoidosis. Respiration 2012; 83:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/63\">",
"      White ES. Infliximab in sarcoidosis: more answers or more questions? Am J Respir Crit Care Med 2006; 174:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/64\">",
"      Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/65\">",
"      Crouser ED, Lozanski G, Fox CC, et al. The CD4+ lymphopenic sarcoidosis phenotype is highly responsive to anti-tumor necrosis factor-{alpha} therapy. Chest 2010; 137:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/66\">",
"      Field S, Regan AO, Sheahan K, Collins P. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin Exp Dermatol 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/67\">",
"      Patel SR. Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report. J Med Case Rep 2009; 3:8573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/68\">",
"      Heffernan MP, Smith DI. Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 2006; 142:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/69\">",
"      Lahmer T, Knopf A, Lanzl I, et al. Using TNF-alpha antagonist adalimumab for treatment for multisystem sarcoidosis: a case study. Rheumatol Int 2012; 32:2367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/70\">",
"      Milman N, Graudal N, Loft A, et al. Effect of the TNF-&alpha; inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J 2012; 6:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/71\">",
"      Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/72\">",
"      Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005; 128:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/73\">",
"      Pocock JM, Vasconcelos JC, Ost&ouml;r AJ. Assessment of anti-TNF-alpha efficacy in rheumatoid arthritis: is 3 months sufficient? Rheumatology (Oxford) 2008; 47:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/74\">",
"      Skoie IM, Wildhagen K, Omdal R. Development of sarcoidosis following etanercept treatment: a report of three cases. Rheumatol Int 2012; 32:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/75\">",
"      Dhaille F, Viseux V, Caudron A, et al. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases. Dermatology 2010; 220:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/76\">",
"      Da&iuml;en CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009; 48:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/77\">",
"      Toussirot E, Berthelot JM, Pertuiset E, et al. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. J Rheumatol 2009; 36:2421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/78\">",
"      Salomon MI, Poon TP, Hsu KC, et al. Membranous glomerulopathy in a patient with sarcoidosis. Arch Pathol 1975; 99:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/79\">",
"      Demeter SL. Myocardial sarcoidosis unresponsive to steroids. Treatment with cyclophosphamide. Chest 1988; 94:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/80\">",
"      Moudgil A, Przygodzki RM, Kher KK. Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil. Pediatr Nephrol 2006; 21:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/81\">",
"      Kouba DJ, Mimouni D, Rencic A, Nousari HC. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 2003; 148:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/82\">",
"      Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 2009; 102:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/83\">",
"      Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 2009; 337:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/84\">",
"      Kalajian AH, Van Meter JR, Callen JP. Sarcoidal anemia and leukopenia treated with methotrexate and mycophenolate mofetil. Arch Dermatol 2009; 145:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/85\">",
"      Marques LJ, Zheng L, Poulakis N, et al. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med 1999; 159:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/86\">",
"      Tong Z, Dai H, Chen B, et al. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest 2003; 124:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/87\">",
"      Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/88\">",
"      Park MK, Babaali H, Gilbert-McClain LI, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/89\">",
"      Kataria YP. Chlorambucil in sarcoidosis. Chest 1980; 78:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/90\">",
"      Sahgal SM, Sharma OP. Fatal herpes simplex infection during chlorambucil therapy for sarcoidosis. J R Soc Med 1984; 77:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/91\">",
"      Hughes GS Jr, Kataria YP, O'Brien TF Jr. Sarcoidosis presenting as biliary cirrhosis: treatment with chlorambucil. South Med J 1983; 76:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/92\">",
"      Israel HL, McComb BL. Chlorambucil treatment of sarcoidosis. Sarcoidosis 1991; 8:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/93\">",
"      Bielory L, Frohman LP. Low-dose cyclosporine therapy of granulomatous optic neuropathy and orbitopathy. Ophthalmology 1991; 98:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/94\">",
"      York EL, Kovithavongs T, Man SF, et al. Cyclosporine and chronic sarcoidosis. Chest 1990; 98:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/95\">",
"      Martinet Y, Pinkston P, Saltini C, et al. Evaluation of the in vitro and in vivo effects of cyclosporine on the lung T-lymphocyte alveolitis of active pulmonary sarcoidosis. Am Rev Respir Dis 1988; 138:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/96\">",
"      Kavanaugh AF, Andrew SL, Cooper B, et al. Cyclosporine therapy of central nervous system sarcoidosis. Am J Med 1987; 82:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/97\">",
"      Wyser CP, van Schalkwyk EM, Alheit B, et al. Treatment of progressive pulmonary sarcoidosis with cyclosporin A. A randomized controlled trial. Am J Respir Crit Care Med 1997; 156:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/98\">",
"      Bachelez H, Senet P, Cadranel J, et al. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001; 137:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/99\">",
"      Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest 2002; 122:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/100\">",
"      Nguyen YT, Dupuy A, Cordoliani F, et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 2004; 50:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/101\">",
"      Judson MA, Silvestri J, Hartung C, et al. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/102\">",
"      Girard N, Cottin V, Hot A, et al. [Opportunistic infections and sarcoidosis]. Rev Mal Respir 2004; 21:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/103\">",
"      Judson MA. Lung transplantation for pulmonary sarcoidosis. Eur Respir J 1998; 11:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/104\">",
"      Milman N, Burton C, Andersen CB, et al. Lung transplantation for end-stage pulmonary sarcoidosis: outcome in a series of seven consecutive patients. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/105\">",
"      Shorr AF, Helman DL, Davies DB, Nathan SD. Sarcoidosis, race, and short-term outcomes following lung transplantation. Chest 2004; 125:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/106\">",
"      Shah L. Lung transplantation in sarcoidosis. Semin Respir Crit Care Med 2007; 28:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/107\">",
"      Wille KM, Gaggar A, Hajari AS, et al. Bronchiolitis obliterans syndrome and survival following lung transplantation for patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/108\">",
"      Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/109\">",
"      Baughman RP, Winget DB, Bowen EH, Lower EE. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/110\">",
"      Hadjiliadis D, Sporn TA, Perfect JR, et al. Outcome of lung transplantation in patients with mycetomas. Chest 2002; 121:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/111\">",
"      Vadnerkar A, Clancy CJ, Celik U, et al. Impact of mold infections in explanted lungs on outcomes of lung transplantation. Transplantation 2010; 89:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/112\">",
"      Fadel E, Mercier O, Mussot S, et al. Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. Eur J Cardiothorac Surg 2010; 38:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/113\">",
"      Scott J, Higenbottam T. Transplantation of the lungs and heart and lung for patients with severe pulmonary complications from sarcoidosis. Sarcoidosis 1990; 7:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/114\">",
"      Johnson BA, Duncan SR, Ohori NP, et al. Recurrence of sarcoidosis in pulmonary allograft recipients. Am Rev Respir Dis 1993; 148:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/115\">",
"      Bj&oslash;rtuft O, Foerster A, Boe J, Geiran O. Single lung transplantation as treatment for end-stage pulmonary sarcoidosis: recurrence of sarcoidosis in two different lung allografts in one patient. J Heart Lung Transplant 1994; 13:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/116\">",
"      Carr&eacute; P, Rouquette I, Durand D, et al. Recurrence of sarcoidosis in a human lung allograft. Transplant Proc 1995; 27:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/117\">",
"      Kazerooni EA, Jackson C, Cascade PN. Sarcoidosis: recurrence of primary disease in transplanted lungs. Radiology 1994; 192:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/11/38074/abstract/118\">",
"      Lingaraju R, Pochettino A, Blumenthal NP, et al. Lung transplant outcomes in white and African American recipients: special focus on acute and chronic rejection. J Heart Lung Transplant 2009; 28:8.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4325 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-9FDBE1AB85-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_11_38074=[""].join("\n");
var outline_f37_11_38074=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MOST COMMONLY USED AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8636968\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H265672417\">",
"      - Pretreatment preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H265672410\">",
"      - Dosage and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8637177\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8637874\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H265672451\">",
"      - Pretreatment preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8637858\">",
"      - Dosage and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8637851\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8637583\">",
"      Leflunomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H98366759\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1807869\">",
"      - Pretreatment preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H98366576\">",
"      - Dosage and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H98366584\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265672239\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10511427\">",
"      Antimalarial agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10511800\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10511807\">",
"      - Dosage and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10511814\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26465141\">",
"      TUMOR NECROSIS FACTOR ANTAGONISTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26465386\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265670874\">",
"      Pretreatment preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265670867\">",
"      Dosage and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26465635\">",
"      Combination with other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26465394\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8637575\">",
"      POTENTIAL TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8637469\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265672173\">",
"      Endothelin receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265670931\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9819076\">",
"      Pentoxifylline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9818587\">",
"      AGENTS THAT ARE AVOIDED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9818649\">",
"      Colchicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9818656\">",
"      Chlorambucil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9818847\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nonsteroidal anti-inflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H376141074\">",
"      Tetracyclines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H376141081\">",
"      Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98367236\">",
"      OPPORTUNISTIC INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ASSESSING RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LUNG TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H265672161\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PATIENT INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44566?source=related_link\">",
"      6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29559?source=related_link\">",
"      Adalimumab for treatment of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/19/17722?source=related_link\">",
"      Cardiac sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/45/22234?source=related_link\">",
"      Chronic beryllium disease (berylliosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/20/19786?source=related_link\">",
"      Cutaneous manifestations of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/14/17638?source=related_link\">",
"      Gastrointestinal sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40406?source=related_link\">",
"      Hepatic granulomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7673?source=related_link\">",
"      Immunomodulator therapy in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37160?source=related_link\">",
"      Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8313?source=related_link\">",
"      Interstitial lung disease in dermatomyositis and polymyositis: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=related_link\">",
"      Leflunomide in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3480?source=related_link\">",
"      Lung transplantation: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35496?source=related_link\">",
"      Malignancy and rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32410?source=related_link\">",
"      Medical management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20616?source=related_link\">",
"      Neurologic sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/35/5683?source=related_link\">",
"      Patient information: Sarcoidosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/14/20705?source=related_link\">",
"      Patient information: Sarcoidosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16889?source=related_link\">",
"      Pulmonary hypertension associated with interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/10/10410?source=related_link\">",
"      Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40438?source=related_link\">",
"      Renal disease in sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/12/11463?source=related_link\">",
"      Sarcoid arthropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=related_link\">",
"      Treatment of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/43/11961?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_11_38075="Cardiac cath chronic MR";
var content_f37_11_38075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Cardiac catheterization in patients with chronic mitral regurgitation (MR)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general",
"agreement that cardiac catheterization is indicated in patients with",
"chronic MR in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; For left ventriculography and hemodynamic measurements when noninvasive tests are not conclusive with respect to the severity of MR, left ventricular function, or the need for surgery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; For hemodynamic measurements when, on noninvasive testing, the pulmonary artery pressure is out of proportion to severity of MR.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; For left ventriculography and hemodynamic measurements when there is a discrepancy regarding the severity of MR between clinical and noninvasive findings.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; For coronary angiography before mitral valve surgery (repair or valve replacement) in patients at risk for coronary artery disease (eg, older age, hypercholesterolemia, hypertension) or with suspected ischemic MR.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or",
"general agreement that cardiac catheterization is not useful in",
"patients with chronic MR in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; For left ventriculography and hemodynamic measurements when valve surgery is not contemplated.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_11_38075=[""].join("\n");
var outline_f37_11_38075=null;
var title_f37_11_38076="Silicone hydrogel contact lens properties";
var content_f37_11_38076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Silicone hydrogel contact lens properties",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Proprietary name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Manufacturer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Material",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dk/t",
"       </td>",
"       <td class=\"subtitle1\">",
"        Modulus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Water content",
"       </td>",
"       <td class=\"subtitle1\">",
"        FDA approved wear",
"       </td>",
"       <td class=\"subtitle1\">",
"        FDA group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PureVision",
"       </td>",
"       <td>",
"        Bausch and Lomb",
"       </td>",
"       <td>",
"        Balafilcon A",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        1.10",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        Up to 30 days CW",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Air Optix Night and Day",
"       </td>",
"       <td>",
"        CibaVision",
"       </td>",
"       <td>",
"        Lotrafilcon A",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        175",
"       </td>",
"       <td>",
"        1.40",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        Up to 30 days CW",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Air Optix",
"       </td>",
"       <td>",
"        CibaVision",
"       </td>",
"       <td>",
"        Lotrafilcon B",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        Up to 6 days CW",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acuvue Advance",
"       </td>",
"       <td>",
"        Vistakon",
"       </td>",
"       <td>",
"        Galyfilcon A",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        0.40",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        DW-2 wk disposal",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acuvue Oasys",
"       </td>",
"       <td>",
"        Vistakon",
"       </td>",
"       <td>",
"        Senfilcon A",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        147",
"       </td>",
"       <td>",
"        0.75",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        Up to 6 days CW",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biofinity",
"       </td>",
"       <td>",
"        CooperVision",
"       </td>",
"       <td>",
"        Comfilcon A",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        0.75",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        Up to 6 days CW",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avaira",
"       </td>",
"       <td>",
"        CooperVision",
"       </td>",
"       <td>",
"        Enfilcon A",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        0.50",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        DW-2 wk disp",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CW: continuous wear; DW: daily wear.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_11_38076=[""].join("\n");
var outline_f37_11_38076=null;
var title_f37_11_38077="Nutrient requirements premature";
var content_f37_11_38077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended daily parenteral and enteral requirements for premature infants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Component (unit)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Parenteral intake, unit/kg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Enteral intake, unit/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Water (mL)",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        150",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Energy (kcal)",
"       </td>",
"       <td>",
"        80 to 100",
"       </td>",
"       <td>",
"        120 to 130",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein (g)",
"       </td>",
"       <td>",
"        3.0 to 3.5",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fat (g)",
"       </td>",
"       <td>",
"        1 to 4",
"       </td>",
"       <td>",
"        5 to 7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbohydrate (g)",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        12 to 14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Electrolytes, minerals, and trace elements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sodium (meq)",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 to 4",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 to 8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Potassium (meq)",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 to 3",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chloride (meq)",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 to 3",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Calcium (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        80 to 120",
"       </td>",
"       <td class=\"sublist_other\">",
"        200 to 220",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Phosphorus (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        60 to 90",
"       </td>",
"       <td class=\"sublist_other\">",
"        100 to 110",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Magnesium (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        9 to 10",
"       </td>",
"       <td class=\"sublist_other\">",
"        7 to 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Zinc (mcg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        350 to 450",
"       </td>",
"       <td class=\"sublist_other\">",
"        1000 to 2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Copper (mcg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        65",
"       </td>",
"       <td class=\"sublist_other\">",
"        65 to 300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chromium (mcg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.4",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.1 to 0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Manganese (mcg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        7.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Vitamins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin A (int. unit)",
"       </td>",
"       <td class=\"sublist_other\">",
"        500",
"       </td>",
"       <td class=\"sublist_other\">",
"        700 to 1500",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin D (int. unit)",
"       </td>",
"       <td class=\"sublist_other\">",
"        160",
"       </td>",
"       <td class=\"sublist_other\">",
"        400*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin E (int. unit)",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.8",
"       </td>",
"       <td class=\"sublist_other\">",
"        6 to 12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin K",
"        <sup>",
"         &bull;",
"        </sup>",
"        (mcg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        80",
"       </td>",
"       <td class=\"sublist_other\">",
"        8 to 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Folic acid (mcg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        56",
"       </td>",
"       <td class=\"sublist_other\">",
"        25 to 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Niacin (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        16.8",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.6 to 4.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pyridoxine (mcg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        180",
"       </td>",
"       <td class=\"sublist_other\">",
"        150 to 210",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Riboflavin (mcg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        150",
"       </td>",
"       <td class=\"sublist_other\">",
"        250 to 360",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thiamine (mcg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        350",
"       </td>",
"       <td class=\"sublist_other\">",
"        180 to 240",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin B12 (mcg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.3",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.1 to 0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin C (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        15 to 25",
"       </td>",
"       <td class=\"sublist_other\">",
"        18 to 24",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Intake is not adjusted for weight.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Does not include 0.5 to 1.0 mg vitamin K given at birth.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Greene HL, Hambidge KM, Schanler RJ, Tsang RC. Guidelines for the use of vitamins, trace elements, calcium, magnesium, and phosphorus in infants and children receiving total parenteral nutrition: report of the Subcommittee on Pediatric Parenteral Nutrient Requirements from the Committee on Clinical Practice Issues of The American Society for Clinical Nutrition. Am J Clin Nutr 1988; 48:1324. American Academy of Pediatrics, Committee on Nutrition. Nutritional needs of low-birth-weight infants. Pediatrics 1985; 75:976. Wharton BA. Wharton BA. Nutrition and feeding of preterm infants. Oxford: Blackwell Scientific Publications, 1987. Tsang RC, Lucas A, Uauy R, Zlotkin S. Nutritional needs of the preterm infant. Williams &amp; Wilkins, Baltimore, 1993. p.288.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_11_38077=[""].join("\n");
var outline_f37_11_38077=null;
var title_f37_11_38078="Treatment of the manifestations of systemic sclerosis";
var content_f37_11_38078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F61685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F61685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 636px\">",
"   <div class=\"ttl\">",
"    Treatment of the manifestations of systemic sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 616px; height: 373px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_11_38078=[""].join("\n");
var outline_f37_11_38078=null;
var title_f37_11_38079="Congenital rubella cataract";
var content_f37_11_38079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital rubella cataract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows cataracts due to congenital rubella syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Centers for Disease Control and Prevention Public Health Image Library.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_11_38079=[""].join("\n");
var outline_f37_11_38079=null;
